Bispecific antibodies effective for T-cell tumor patients with T-cell dysfunction
By developing a bispecific antigen-binding molecule that can specifically bind to both T-cell tumor cells and normal T cells, the challenge of tumor treatment in T-cell dysfunction has been solved, achieving highly efficient killing and treatment of T-cell tumors.
Patent Information
- Application Number
- CN202580028310.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-17
- Filing Date
- 2025-04-16
- Publication Date
- 2026-11-17
AI Technical Summary
Current technologies are insufficient to effectively treat T-cell tumors in a state of T-cell dysfunction, especially adult T-cell leukemia (ATL), due to the immune avoidance mechanisms of tumor cells leading to poor treatment outcomes. Including anti-PD-1 antibody therapy, which may lead to disease progression.
Develop a bispecific antigen-binding molecule that can specifically bind to target tumor antigens that bind specifically to T-cell tumor cells and subtype-specific target antigens on the normal T-cell side, mobilize effector cells to kill tumor cells, and avoid activation of normal T cells, including the use of TRBC1 and TRBC2 as target antigens on the normal T-cell side.
In a state of T cell dysfunction, it can effectively induce the cytotoxicity of tumor cells, kill malignant tumor T cells, and at the same time retain a sufficient number of normal T cells to achieve high therapeutic effects.
Smart Images

Figure CN123124994A_ABST
Abstract
Description
Technical Field
[0001] This application claims priority to Japanese Patent Application No. 2024-066502, filed on April 17, 2024, the entire contents of which are incorporated herein by reference in particular in their public form.
[0002] This invention relates to therapeutic agents for T-cell tumors in subjects with T-cell dysfunction, comprising a bispecific antigen-binding molecule. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to a target tumor antigen expressed on T-cell tumor cells, and at least one portion that specifically binds to a subtyped antigen that is a target antigen on normal T cells. This invention relates to the bispecific antigen-binding molecule and its uses, and to treatment methods for T-cell tumors including administering the bispecific antigen-binding molecule to a subject. Background Technology
[0003] Bispecific T-cell engager antibodies have been developed that can induce T-cell activity in target cells and selectively kill target cells in vivo. A bispecific antibody that simultaneously recognizes human CD19 and CD3 antigens (Blinatumomab) has been approved for marketing as a treatment for relapsed / refractory B-cell acute lymphoblastic leukemia (ALL) (Goebeler, ME and R. Bargou, Blinatumomab: a CD19 / CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. LeukLymphoma, 2016. 57(5): p. 1021-32.). Blinatumomab is a bispecific T-cell inducing antibody (BiTETM) and has the structure of a single-chain antibody obtained by linking two single-chain variable region fragments (scFv) with short adapters. Besides blinatumomab, many bispecific antibodies targeting CD3 antigen and tumor cell antigens have been developed in recent years.
[0004] Lymphoid malignancies are broadly classified into B-cell malignancies and T-cell malignancies. Bispecific antibodies are mostly developed for the treatment of B-cell malignancies. Acute osteoblastic leukemia (AIL) cells and normal osteoblastic progenitor cells share the same cell surface antigens. Therefore, bispecific antibodies targeting tumor cell antigens of AIL attack not only leukemia cells but also normal osteoblastic progenitor cells, causing neutropenia and leading to febrile neutropenia, which is difficult to treat. In immunotherapy for B-cell malignancies, the target antigens are also expressed in normal B cells. Bispecific antibodies targeting tumor cell antigens of B-cell malignancies attack not only tumor cells but also normal B-cell progenitor cells, causing B-cell immunodeficiency and preventing antibody production. However, B-cell immunodeficiency can be prevented by regularly administering immunoglobulin preparations (Maciocia PM, et al., Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017 Dec;23(12):1416-1423.).
[0005] On the other hand, immunotherapy for T-cell malignancies is limited. Since CD3 is expressed equally in both normal T cells and tumor T cells, bispecific antibodies targeting both CD3 and tumor antigens can simultaneously bind to both CD3 antigens expressed in T-cell malignancies and target antigens expressed in T-cell malignancies, thus linking the malignant cells together. Figure 1A Therefore, it is highly likely that the therapeutic effect of bispecific antibodies will not be fully realized. Furthermore, there is the problem of not knowing the target antigens that recognize normal T cells and malignant cells. Defective T cell formation due to targeting pan-T cell antigens can lead to severe and unacceptable immunodeficiency (Maciocia PM, et al., ibid.).
[0006] In addition to the CD3 antigen, bispecific antibodies that utilize TRGV9 expressed in γδT cells as a target on the effector cell (T cell) side also exist (WO2021 / 173896A1). However, γδT cells constitute only a few percent of the total number of T cells, thus posing a problem of not being able to mobilize a sufficient number of T cells to kill tumor cells and achieve therapeutic effects.
[0007] Furthermore, it is known that some T-cell malignancies, such as adult T-cell leukemia (ATL), can lead to T-cell dysfunction due to immune avoidance by tumor cells. ATL is a disease that eventually develops into ATL after a long period of accumulation of gene mutations following infection with HTLV-1 (human T-cell leukemia virus type 1) (Kataoka K, et al., Prognosticrelevance of integrated genetic profiling in adult T-cell leukemia / lymphoma.Blood. 2018 Jan 11;131(2):215-225. doi: 10.1182 / blood-2017-01-761874. Epub2017 Oct 30. PMID: 29084771; PMCID: PMC5757690.). HTLV-1 infected cells are in a state of continuous activation of the TCR and NFκB signaling pathways due to numerous gene mutations, eventually becoming clonal proliferating ATL cells (Benjy J.Y. Tan, et al., HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia / lymphoma. J Clin Invest. 2021;131(24):e150472. https: / / doi.org / 10.1172 / JCI150472.). ATL cells exhibit a Treg phenotype, highly expressing co-inhibitory molecules such as CTLA4 (cytotoxic T lymphocyte antigen 4) and LAG3 (lymphocyte activation gene 3), thus inhibiting the maturation of antigen-presenting cells (APCs). Furthermore, the CD80 / 86 of APCs binds to the highly expressed CTLA4 in ATL cells, inhibiting the binding of CD28 of normal T cells to CD80 / 86 of APCs, thereby causing T cell anergy in normal T cells. On the other hand, ATL cells highly express HLA class II (human leukocyte antigen class II), so they can also become antigen-presenting cells. However, since ATL cells do not express CD80 / 86, both naive T cells and effector T cells can cause T cell anergy (Benjy JYTan, et al., ibid.).
[0008] Immunotherapy based on immunosuppressive checkpoint inhibitors is being developed to counteract the immune evasion mechanisms of cancer cells. However, due to the high expression of PDL-1 (programmed cell death ligand 1) in ATL cells, there have been reported cases of rapid deterioration in ATL patients after administration of the anti-PD-1 antibody nivolumab (Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N Engl J Med. 2018 May 17;378(20):1947-1948. doi: 10.1056 / NEJMc1803181. PMID: 29768155.). Studies using mouse models have shown that loss of PD-1 alters oncogenic signaling pathways in T cells, promoting the development of T-cell lymphoma (Wartewig T, Kurgyis Z, Keppler S et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 2017; 552: 121-125.). Therefore, treatment with anti-PD-1 antibodies may not be effective for T-cell malignancies, including ATL. Summary of the Invention
[0009] The problem that the invention aims to solve There is a need for new treatment methods for T-cell tumors that can achieve high therapeutic efficacy even when used to treat T-cell tumors in subjects with T-cell dysfunction.
[0010] Therefore, the subject of this invention is to provide a novel treatment method for T-cell tumors that can induce cytotoxicity in tumor cells and can be used to treat T-cell tumors in subjects with T-cell dysfunction.
[0011] Methods for solving problems To address the aforementioned issues, the inventors conducted repeated and in-depth research, discovering that bispecific antigen-binding molecules, which specifically bind to target tumor antigens expressed in T-cell tumor cells and subtyped target antigens on the normal T-cell side, mobilize effector cells (normal T cells) and induce cytotoxicity in tumor cells. Furthermore, the inventors found that by using antigens with subtypes expressed between T-cell tumor cells and normal T cells as target antigens on the normal T-cell side of the bispecific antigen-binding molecule, it is possible to kill T-cell malignant tumor cells while preserving sufficient normal T cells. Moreover, the inventors also discovered that the aforementioned bispecific antigen-binding molecule can induce cytotoxic activity even in T-cell tumor patients with T-cell dysfunction. This invention is based on the above insights.
[0012] According to the present invention, the following invention is provided.
[0013] [1] A therapeutic agent, which is a therapeutic agent for T-cell tumors in subjects with T-cell dysfunction containing bispecific antigen-binding molecules, wherein, Bispecific antigen-binding molecules include: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors.
[0014] [2] According to the therapeutic agent described in [1], wherein the subtype of the normal T cell side target antigen is any subtype of antigen subtype that is not expressed in T cell tumor cells.
[0015] [3] According to the therapeutic agent described in [1] or [2], the antigen with a subtype that is a normal T cell side target antigen is TRBC (T cell receptor β constant region). The subtype expressed in T-cell tumor cells is TRBC1. The subtype of target antigen on the side of normal T cells is TRBC2.
[0016] [4] According to the therapeutic agent described in [1] or [2], wherein the subtype of the antigen that serves as a target antigen for normal T cells is TRBC, The subtype expressed in T-cell tumor cells is TRBC2. The subtype of target antigen on the side of normal T cells is TRBC1.
[0017] [5] According to the therapeutic agent described in [1] or [2], wherein the subtype of the antigen that serves as a target antigen for normal T cells is TRBC, T-cell tumor cells are TRBC1-negative and TRBC2-negative. The subtypes of target antigens on normal T cells are TRBC1 or TRBC2.
[0018] [6] The therapeutic agent according to any one of [1]-[5], wherein the target tumor antigen expressed in T-cell tumor cells is selected from any one of CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4, CXCR7, TIGIT, CADM1, GPR15, CXCR5, CXCL13, SLAM, ICOS, CD134, CXCR3, anaplastic lymphoma kinase, CD30, ST2(L), CCR5, Notch1, CD38, CD1a, CCR9 (CD199), CD47, IL-7Rα (CD127) and CD40L (CD154).
[0019] [7] The therapeutic agent according to any one of [1]-[6], wherein the subtype of the normal T cell side target antigen is TRBC1, The bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC1 on normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:15.
[0020] [8] The therapeutic agent according to [7], wherein at least one portion specifically binds to TRBC1 of normal T cells. Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or It contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149.
[0021] [9] The therapeutic agent according to any one of [1]-[6], wherein the subtype of the normal T cell side target antigen is TRBC2, The bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC2 on normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21.
[0022]
[10] According to the therapeutic agent of [9], wherein at least one portion that specifically binds to TRBC2 of normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7.
[0023]
[11] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CCR4, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR4, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:22 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:23, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:24 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:25 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:26 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:27.
[0024]
[12] The therapeutic agent according to
[11] , wherein at least one portion specifically binding to CCR4 comprises: The heavy chain variable region VH is at least 90% identical to the amino acid sequence described in SEQ ID NO:8, and the light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:9.
[0025]
[13] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CD1a, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CD1a, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:34 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:35, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:36 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:37 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:38 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:39.
[0026]
[14] The therapeutic agent according to
[13] , wherein at least one portion specifically binding to CD1a comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:40. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:41.
[0027]
[15] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CCR9, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR9, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:101 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:102, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:103 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:104 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:105, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:106.
[0028]
[16] The therapeutic agent according to
[15] , wherein at least one portion specifically binding to CCR9 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:131. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:132.
[0029]
[17] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CXCR4. The bispecific antigen-binding molecule comprises at least one part that specifically binds to CXCR4, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:107 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:108, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:109 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:110 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:111 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:112.
[0030]
[18] The therapeutic agent according to
[17] , wherein at least one portion specifically binding to CXCR4 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:133. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:134.
[0031]
[19] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is TIGIT. The bispecific antigen-binding molecule comprises at least one part that specifically binds to TIGIT, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:89 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:90, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:91 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:92 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:93 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:94.
[0032]
[20] The therapeutic agent according to
[19] , wherein at least one portion specifically binding to TIGIT comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:135. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:136.
[0033]
[21] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CCR8, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR8, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:95 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:96, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:97 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:98 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:99 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:100.
[0034]
[22] The therapeutic agent according to
[21] , wherein at least one portion specifically binding to CCR8 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:137. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:138.
[0035]
[23] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CD30. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD30, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:113 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:114, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:115 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:116 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:117 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:118.
[0036]
[24] The therapeutic agent according to
[23] , wherein at least one portion specifically binding to CD30 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:139. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:140.
[0037]
[25] The therapeutic agent according to any one of [1]-
[10] , wherein the target tumor antigen expressed in T-cell tumor cells is CD40L (CD154). The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD40L (CD154), wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:119 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:120, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:121 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:122 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:123 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:124.
[0038]
[26] The therapeutic agent according to
[25] , wherein at least one portion specifically binding to CD40L (CD154) comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:141. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:142.
[0039]
[27] The therapeutic agent according to any one of [1]-
[26] , wherein the T-cell tumor is T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma or mature T-cell tumor, preferably selected from any one of adult T-cell leukemia (ATL), peripheral T-cell lymphoma (PTCL) and T-cell acute lymphoblastic leukemia (TALL).
[0040]
[28] A therapeutic agent, which is a therapeutic agent of any one of [1]-
[27] for treating a subject with a T-cell tumor in a state of T-cell dysfunction, wherein the aforementioned treatment method comprises: determining a subtype expressed in the subject's T-cell tumor cells, and administering the therapeutic agent to the subject; the therapeutic agent comprises a bispecific antigen-binding molecule comprising at least one portion that specifically binds to a normal T-cell side-target antigen, the subtype of which is different from the subtype determined to be expressed in the subject's T-cell tumor cells.
[0041]
[29] A therapeutic agent for T-cell tumors in a subject with T-cell dysfunction, comprising a bispecific antigen-binding molecule, wherein the aforementioned bispecific antigen-binding molecule comprises: At least one portion of the target tumor antigen specifically binds to T-cell tumor cells expressed in tumor cells, and At least one portion of the substance specifically binds to either TRBC1 or TRBC2 expressed in normal T cells.
[0042]
[30] According to the therapeutic agent of
[29] , when the T-cell tumor cells are TRBC1 positive, the aforementioned bispecific antigen-binding molecule includes at least one portion that specifically binds to TRBC2 expressed in normal T cells, and when the T-cell tumor cells are TRBC2 positive, the aforementioned bispecific antigen-binding molecule includes at least one portion that specifically binds to TRBC1 expressed in normal T cells.
[0043]
[31] According to the therapeutic agent of
[29] or
[30] , wherein the bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC1 expressed in normal T cells, the at least one portion comprising a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:15.
[0044]
[32] According to the therapeutic agent described in
[31] , wherein at least one portion specifically binds to TRBC1 expressed in normal T cells. Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or It contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149.
[0045]
[33] According to the therapeutic agent of
[29] or
[30] , wherein the bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC2 expressed in normal T cells, the at least one portion comprising a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21.
[0046]
[34] According to the therapeutic agent of
[33] , wherein at least one portion specifically binds to TRBC2 expressed in normal T cells comprises: The heavy chain variable region VH is at least 90% identical to the amino acid sequence described in SEQ ID NO:6, and the light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:7.
[0047]
[35] The therapeutic agent according to any one of
[29] -
[34] , wherein at least one portion that specifically binds to TRBC1 or TRBC2 expressed in normal T cells is an scFv or Fab fragment.
[0048]
[36] The therapeutic agent according to any one of
[29] -
[35] , wherein the target tumor antigen expressed in T-cell tumor cells is selected from any one of CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4, CXCR7, TIGIT, CADM1, GPR15, CXCR5, CXCL13, SLAM, ICOS, CD134, CXCR3, anaplastic lymphoma kinase, CD30, ST2(L), CCR5, Notch1, CD38, CD1a, CCR9 (CD199), CD47, IL-7Rα (CD127) and CD40L (CD154).
[0049]
[37] The therapeutic agent according to any one of
[29] -
[36] , wherein the bispecific antigen-binding molecule comprises at least one portion that specifically binds to CCR4, the at least one portion comprising a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:22 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:23, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:24 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:25 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:26 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:27.
[0050]
[38] The therapeutic agent according to
[37] , wherein at least one portion specifically binding to CCR4 comprises: The heavy chain variable region VH is at least 90% identical to the amino acid sequence described in SEQ ID NO:8, and the light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:9.
[0051]
[39] The therapeutic agent according to any one of
[29] -
[36] , wherein the bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD1a, the at least one portion comprising a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:34 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:35, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:36 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:37 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:38 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:39.
[0052]
[40] The therapeutic agent according to
[39] , wherein at least one portion specifically binding to CD1a comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:40. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:41.
[0053]
[41] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is CCR9, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR9, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:101 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:102, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:103 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:104 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:105, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:106.
[0054]
[42] According to the therapeutic agent of
[41] , wherein at least one portion specifically binding to CCR9 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:131. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:132.
[0055]
[43] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is CXCR4. The bispecific antigen-binding molecule comprises at least one part that specifically binds to CXCR4, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:107 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:108, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:109 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:110 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:111 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:112.
[0056]
[44] The therapeutic agent according to
[43] , wherein at least one portion specifically binding to CXCR4 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:133. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:134.
[0057]
[45] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is TIGIT. The bispecific antigen-binding molecule comprises at least one part that specifically binds to TIGIT, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:89 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:90, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:91 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:92 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:93 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:94.
[0058]
[46] The therapeutic agent according to
[45] , wherein at least one portion specifically binding to TIGIT comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:135. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:136.
[0059]
[47] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is CCR8, The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR8, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:95 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:96, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:97 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:98 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:99 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:100.
[0060]
[48] The therapeutic agent according to
[47] , wherein at least one portion specifically binding to CCR8 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:137. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:138.
[0061]
[49] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is CD30. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD30, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:113 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:114, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:115 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:116 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:117 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:118.
[0062]
[50] The therapeutic agent according to
[49] , wherein at least one portion specifically binding to CD30 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:139. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:140.
[0063]
[51] The therapeutic agent according to any one of
[29] -
[36] , wherein the target tumor antigen expressed in T-cell tumor cells is CD40L (CD154). The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD40L (CD154), wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:119 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:120, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:121 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:122 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:123 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:124.
[0064]
[52] The therapeutic agent according to
[51] , wherein at least one portion specifically binding to CD40L (CD154) comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:141. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:142.
[0065]
[53] The therapeutic agent according to any one of
[29] -
[52] , wherein at least one portion that specifically binds to the target tumor antigen expressed in T-cell tumor cells comprises an scFv or Fab fragment.
[0066]
[54] The therapeutic agent according to any one of
[29] -
[53] , wherein the T-cell tumor is T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma or mature T-cell tumor, preferably selected from any one of adult T-cell leukemia (ATL), peripheral T-cell lymphoma (PTCL) and T-cell acute lymphoblastic leukemia (TALL).
[0067]
[55] The therapeutic agent according to any one of
[29] -
[54] , wherein the bispecific antigen-binding molecule is administered in combination with chemotherapeutic agents, radiation and / or other agents used in cancer immunotherapy.
[0068]
[56] A bispecific antigen-binding molecule, which is a bispecific antigen-binding molecule for the treatment of T-cell tumors in subjects with T-cell dysfunction, comprising: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Among them, at least one portion that specifically binds to the subtype of antigen that is a target antigen of normal T cells is at least one portion that specifically binds to TRBC1 or TRBC2 (T cell receptor β constant region 1 or 2) of normal T cells.
[0069]
[57] According to the bispecific antigen-binding molecule described in
[56] , at least one portion that specifically binds to TRBC1 expressed in normal T cells comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:15.
[0070]
[58] According to the bispecific antigen-binding molecule described in
[57] , at least one portion specifically binds to TRBC1 expressed in normal T cells. Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or It contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149.
[0071]
[59] According to the bispecific antigen-binding molecule described in
[56] , at least one portion that specifically binds to TRBC2 expressed in normal T cells comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21.
[0072]
[60] According to the bispecific antigen-binding molecule of
[59] , at least one portion that specifically binds to TRBC2 expressed in normal T cells comprises: The heavy chain variable region VH is at least 90% identical to the amino acid sequence described in SEQ ID NO:6, and the light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:7.
[0073]
[61] A bispecific antigen-binding molecule according to any one of
[56] -
[60] , wherein the target tumor antigen expressed in T-cell tumor cells is selected from any one of CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4, CXCR7, TIGIT, CADM1, GPR15, CXCR5, CXCL13, SLAM, ICOS, CD134, CXCR3, anaplastic lymphoma kinase, CD30, ST2(L), CCR5, Notch1, CD38, CD1a, CCR9 (CD199), CD47, IL-7Rα (CD127), and CD40L (CD154).
[0074]
[62] According to the bispecific antigen-binding molecule described in
[61] , at least one portion that specifically binds to CCR4 comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:22 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:23, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:24 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:25 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:26 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:27.
[0075]
[63] According to the bispecific antigen-binding molecule of
[62] , wherein at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:8 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:9.
[0076]
[64] According to the bispecific antigen-binding molecule of
[61] , at least one portion that specifically binds to CD1a comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:34 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:35, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:36 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:37 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:38 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:39.
[0077]
[65] According to the bispecific antigen-binding molecule of
[64] , wherein at least one portion specifically binding to CD1a comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:40. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:41.
[0078]
[66] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is CCR9. The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR9, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:101 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:102, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:103 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:104 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:105, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:106.
[0079]
[67] According to the bispecific antigen-binding molecule of
[66] , wherein at least one portion specifically binding to CCR9 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:131. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:132.
[0080]
[68] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is CXCR4. The bispecific antigen-binding molecule comprises at least one part that specifically binds to CXCR4, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:107 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:108, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:109 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:110 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:111 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:112.
[0081]
[69] According to the bispecific antigen-binding molecule of
[68] , wherein at least one portion specifically binding to CXCR4 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:133. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:134.
[0082]
[70] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is TIGIT. The bispecific antigen-binding molecule comprises at least one part that specifically binds to TIGIT, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:89 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:90, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:91 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:92 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:93 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:94.
[0083]
[71] According to the bispecific antigen-binding molecule of
[70] , wherein at least one portion specifically binding to TIGIT comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:135. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:136.
[0084]
[72] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is CCR8. The bispecific antigen-binding molecule comprises at least one part that specifically binds to CCR8, wherein the at least one part comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:95 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:96, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:97 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:98 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:99 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:100.
[0085]
[73] According to the bispecific antigen-binding molecule of
[72] , wherein at least one portion specifically binding to CCR8 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:137. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:138.
[0086]
[74] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is CD30. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD30, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:113 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:114, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:115 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:116 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:117 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:118.
[0087]
[75] According to the bispecific antigen-binding molecule of
[74] , wherein at least one portion specifically binding to CD30 comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:139. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:140.
[0088]
[76] According to the bispecific antigen-binding molecule described in
[61] , the target tumor antigen expressed in T cell tumor cells is CD40L (CD154). The bispecific antigen-binding molecule comprises at least one portion that specifically binds to CD40L (CD154), wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:119 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:120, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:121 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:122 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:123 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:124.
[0089]
[77] According to the bispecific antigen-binding molecule of
[76] , wherein at least one portion specifically binding to CD40L (CD154) comprises: The heavy chain variable region VH, and [other components] are at least 90% identical to the amino acid sequence described in SEQ ID NO:141. The light chain variable region VL is at least 90% identical to the amino acid sequence described in SEQ ID NO:142.
[0090]
[78] A treatment for T-cell tumors in subjects with T-cell dysfunction, comprising administering to a subject with a T-cell tumor any of the bispecific antigen-binding molecules described in any of
[56] -
[77] .
[0091]
[79] A bispecific antigen-binding molecule, which is a bispecific antigen-binding molecule for the treatment of T-cell tumors in subjects with T-cell dysfunction, comprising: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors.
[0092]
[80] A treatment method for treating T-cell tumors in a subject with T-cell dysfunction, the method comprising administering a bispecific antigen-binding molecule to the subject having a T-cell tumor, wherein, Bispecific antigen-binding molecules include: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors.
[0093]
[81] The treatment method according to
[80] further includes identifying a subtype expressed in the subject's T-cell tumor cells, the bispecific antigen-binding molecule comprising at least one portion specifically binding to a normal T-cell side-target antigen, the subtype of said normal T-cell side-target antigen being different from the subtype identified as being expressed in the subject's T-cell tumor cells.
[0094]
[82] Use of a bispecific antigen-binding molecule in the manufacture of a medicament for treating T-cell tumors in subjects with T-cell dysfunction, wherein the bispecific antigen-binding molecule comprises: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors. Attached Figure Description
[0095] Figure 1A : Figure 1A This indicates a state in which a bispecific antibody simultaneously binds to both CD3 expressed on tumor cells and the target antigen expressed on tumor cells, thus bridging the tumor cells together.
[0096] Figure 1B : Figure 1B This diagram illustrates the concept of the present invention. The bispecific antigen-binding molecule of the present invention recognizes a target antigen expressed in (T-cell) tumor cells and an antigen with a subtype that serves as a target antigen on the normal T-cell side (in the diagram, the subtype expressed in T lymphocytes is TRBC1), representing a state that bridges tumor cells and T lymphocytes. In the diagram, the bispecific antigen-binding molecule binds simultaneously to both the TRBC1 antigen on T lymphocytes and the target antigen expressed on tumor cells. The TRBC2 subtype is expressed not only in tumor cells but also in T lymphocytes. In the diagram, the bispecific antigen-binding molecule does not recognize T lymphocytes expressing the TRBC2 subtype.
[0097] Figure 2A : Figure 2A The structures of the bispecific antibodies prepared in the examples are shown. The Fab-scFv type has a structure in which an scFv bound to one antigen is linked to a Fab moiety bound to another antigen using a linker. The Fab-scFv-Fc type has a structure in which two scFvs bound to one antigen are linked to a Fab moiety bound to another antigen using linkers, and further has an Fc structure. The Fab-Fc-scFv type has a structure in which an scFv bound to another antigen is attached to the C-terminus of an IgG bound to one antigen. A: The portion bound to one antigen; B: The portion bound to another antigen.
[0098] Figure 2B : Figure 2BThe VH and VL amino acid sequences of the anti-TRBC1 antibody, humanized anti-TRBC1 antibody, anti-TRBC2 antibody, and anti-CCR4 antibody used in the fabrication of the bispecific antibodies are shown. The underlined portions indicate the respective CDRs. The VH and VL amino acid sequences of the anti-CCR4 antibody are those described in SEQ ID NO:9 and 14 of Japanese Patent No. 4052515 (Humanized CDR Transplantation Antibody and Antibody Fragment thereof). The VH and VL amino acid sequences of the humanized anti-TRBC1 antibody are those described in SEQ ID NO:9 and 19 of Japanese Patent No. 7177794 (corresponding to WO2018 / 224844). The VH and VL amino acid sequences of the anti-TRBC1 antibody are those described in SEQ ID NO:15 and 16 of US10730942 (Protein-Based T-Cell Receptor Knockdown). The VH and VL amino acid sequences of the anti-TRBC2 antibody are the sequences of the VH domain of hJOV-1 in WO2020 / 089644 (SEQ ID NO:1 of WO2020 / 089644) with three amino acid substitutions for T28K, Y32F, and A100N (Table 1 (page 23) of WO2020 / 089644) and the VL domain of hJOV-1 (SEQ ID NO:2 of WO2020 / 089644). The underlined CDRs are defined according to the Kabat numbering scheme.
[0099] Figure 3A ―K: Figure 3A —K shows the amino acid sequences of the heavy and light chains that constitute the bispecific antibody prepared in Example 1.
[0100] Figure 4A : Figure 4A The increase in the percentage of TRBC1-positive cells after the addition of anti-TRBC1 antibody is shown. N=3.
[0101] Figure 4B : Figure 4B The diagram shows that live cells were stained with Fixable Viability Dye eFluor™ 780 and gated. After being expanded with FSC and SSC, the major cell populations were circled, and then expanded with CD3 and TRBC1 to calculate the percentage of TRBC1 positive cells in CD3 positive cells (T cells).
[0102] Figure 5A : Figure 5A The addition of anti-TRBC1 antibody shows an increase in cytotoxic T cells.
[0103] Figure 5B : Figure 5BThe diagram shows live cells stained with Fixable Viability Dye eFluor™ 780, gated, and expanded using FSC and SSC. After outlining the major cell populations, TRBC1-positive cells were used for gating, and the cells were expanded using CD27 and CD45RA to calculate the proportions of each cell group within TRBC1-positive cells. *Effective memory (EM): Primarily circulates in secondary lymphoid tissues (lymph nodes) and peripheral tissues. Upon re-exposure to the same antigen, it rapidly produces live cytokines to initiate an immune response. Central memory (CM): Residing in secondary lymphoid tissues (lymph nodes), it displays an antigen response. Naive: T cells not exposed to the antigen. EM T cells re-expressing CD45RA (EMRA): Effector memory cells that eventually differentiate. N=3.
[0104] Figure 6A : Figure 6A The percentage of activation markers in TRBC1-positive cells is shown. (N=3, *Data for Day 0 only, N=2, for perforin) Figure 6B : Figure 6B This is a graph showing the positive rates of each marker in TRBC1-positive cells after gating them and expanding them with CD25 and CD69.
[0105] Figure 6C : Figure 6C This is a graph showing the percentage of granzyme B positivity in TRBC1-positive cells, calculated using TRBC1 and granzyme B expansion.
[0106] Figure 6D : Figure 6D This is a graph showing the perforin positivity rate in TRBC1-positive cells, calculated using TRBC1 and perforin. Data are expressed as mean (SD).
[0107] Figure 7A : Figure 7A The change in the percentage of PD-1 positive cells induced by the addition of anti-TRBC1 antibody is shown. N=3.
[0108] Figure 7B : Figure 7B The method involves staining live cells with Fixable Viability Dye eFluor™ 780, gating them, developing them with FSC and SSC, outlining the major cell populations, developing them with TRBC1 and PD-1, and calculating the ratio of PD-1 positive cells among TRBC1 positive cells.
[0109] Figure 8 : Figure 8 This illustrates the quantification of cytokine release from T-LAK cells stimulated with anti-TRBC1 antibody.
[0110] Figure 9 : Figure 9 The results show an increase in the number of cells, including TRBC2-positive T cells, after the addition of anti-TRBC2 antibody.
[0111] Figure 10 (a) is a graph showing the increase in cytotoxic T cells induced by the addition of anti-TRBC2 antibody. (b) shows the gating of live cells with Fixed Viability Dye eFluor™ 780 staining, expansion with FSC and SSC, selection of major cell populations, gating with CD3-positive and TRBC1-negative cells (gating with TRBC2-positive cells), expansion with CD27 and CD45RA, and calculation of the proportions of each class of fractions in TRBC2-positive cells (N=3). EM: effector memory, CM: central memory, EMRA: EM T cells reexpressing CD45RA.
[0112] Figure 11A -B: (a) shows the positivity rate (%) of activated markers in TRBC2-positive cells (N=3). (b) is a graph showing the positivity rate of each marker in TRBC2-positive cells after gating with CD25 and CD69. (c) is a graph showing the positivity rate of granzyme B in TRBC2-positive cells after developing with TRBC1 and granzyme B. (d) is a graph showing the positivity rate of perforin in TRBC2-positive cells after developing with TRBC1 and perforin. Data are expressed as mean (SD).
[0113] Figure 12 (a) shows the change in the percentage of PD-1 positive cells induced by the addition of anti-TRBC2 antibody (N=3). (b) is a graph showing the percentage of PD-1 positive cells among TRBC2 positive cells after gating with Fixed Viability Dye eFluor™ 780, developing with FSC and SSC, outlining the major cell populations, developing with TRBC1 and PD-1, and calculating the percentage of PD-1 positive cells among TRBC2 positive cells.
[0114] Figure 13 : Figure 13 The figures show the quantification of cytokine release from T-LAK cells stimulated with anti-TRBC1 antibody. The vertical axis of each figure represents concentration.
[0115] Figure 14A —C: Figure 14A —C indicates the cytotoxic activity of the bispecific antibodies CCR0001 and CCR0004.
[0116] Figure 15 : Figure 15The cytotoxic activity of the bispecific antibodies CD1a1001 and CD1a1004 was demonstrated.
[0117] Figure 16 : Figure 16 The anti-CCR4 / anti-TRBC2 bispecific antibody was shown to have cytotoxic activity against the MT-2 cell line from ATL.
[0118] Figure 17 : Figure 17 The anti-CD1a / anti-TRBC2 bispecific antibody was demonstrated to have cytotoxic activity against the TALL cell line JM (expressing CD1a and TRBC1).
[0119] Figure 18 : Figure 18 The anti-CCR9 / anti-TRBC1 bispecific antibody was demonstrated to have cytotoxic activity against the CCRF-CEM9 cell line (expressing CCR9 and TRBC2) from TALL.
[0120] Figure 19 : Figure 19 The anti-CXCR4 / anti-TRBC1 bispecific antibody was demonstrated to have cytotoxic activity against the CCRF-CEM9 cell line (expressing CXCR4 and TRBC2) from TALL.
[0121] Figure 20 : Figure 20 The anti-CCR8 / anti-TRBC1 bispecific antibody was demonstrated to have cytotoxic activity against the MT-1 cell line (expressing CCR8) from ATL.
[0122] Figure 21 : Figure 21 The anti-TIGIT / anti-TRBC1 bispecific antibody was shown to have cytotoxic activity against the ILT-Mat cell line (expressing TIGIT) from ATL.
[0123] Figure 22 : Figure 22 The anti-CD30 / anti-TRBC1 bispecific antibody was shown to have cytotoxic activity against DL40 cell line (expressing CD30) from PTCL.
[0124] Figure 23 : Figure 23 The anti-CD40L / anti-TRBC1 bispecific antibody was shown to have cytotoxic activity against the MOLT3 cell line (expressing CD40L) from TALL.
[0125] Figure 24 : Figure 24The results were obtained by adding T-LAK to HPB-ALL cells, a TALL cell line expressing CD3, and HPB-ALLCD3 KO cells with CD3 knockout, and measuring the cytotoxic activities of the anti-CD1a / anti-CD3 bispecific antibody CD1a1016 (a), as well as the anti-CD1a antibody and the anti-CD1a / anti-TRBC1 bispecific antibody CD1a1005 (b).
[0126] Figure 25 : Figure 25 The results were obtained by sensitizing T-LAK cells with anti-TRBC2 antibody after adding CCRF-CEM9 cells from TALL expressing TRBC2 and JM cells from TALL expressing TRBC1, and measuring the cytotoxic activity of the anti-CD1a / anti-TRBC2 bispecific antibody CD1a1006.
[0127] Figure 26 : Figure 26 This is a graph showing the IVIS measurements for each group of NOG mice that received tumor cell transplants on days 14 and 28.
[0128] Figure 27 : Figure 27 This is an image showing the tumor distribution in NOG mice that have had tumor cells transplanted.
[0129] Figure 28 : Figure 28 The percentages of PD-1 and CTLA-4 positive cells are shown in normal T cells that are CD3 positive, CD4 positive, and CADM1 negative.
[0130] Figure 29 : Figure 29 This study demonstrates the cytotoxic activity of PBMCs derived from healthy individuals (healthy individual 1) and PBMCs derived from ATL patients (ATL patient 1 and ATL patient 2) against luciferase-positive MOLT-4-Luc cells under the addition of anti-CD1a / anti-TRBC1 bispecific antibody (CD1a1005).
[0131] Figure 30 : Figure 30 This is a graph showing the function of CD8-positive T cells in PBMCs from healthy individuals and PBMCs from ATL patients, analyzed using single-cell RNA-Seq.
[0132] Figure 31 : Figure 31 This is a graph showing the cytotoxic activity of PBMCs from healthy individuals and PBMCs from ATL patients against luciferase-positive MOLT-4-Luc cells under conditions with the addition of anti-CD1a / anti-TRBC2 bispecific antibodies. Detailed Implementation
[0133] The following description of the invention is sometimes based on representative embodiments and specific examples, but the invention is not limited to such embodiments. It should be noted that the numerical range indicated by “~” in this specification refers to the range of values described before and after “~” as a lower and upper limit value.
[0134] This invention relates to the treatment of T-cell tumors in subjects with T-cell dysfunction.
[0135] Hematologic malignancies are broadly classified into lymphocytic tumors and bone marrow tumors based on the origin or maturity of their tumor cells. Lymphocytic tumors can be further divided into T-cell tumors and B-cell tumors. Lymphocytic tumors originate from lymphocyte precursor cells, while bone marrow tumors originate from bone marrow precursor cells. Malignant T-lymphocytes are T-cell tumor cells, and malignant B-lymphocytes are B-cell tumor cells.
[0136] In this specification, "T-cell tumors" include T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma and mature T-cell tumors, but are not limited to these as long as they are tumors of T cells or their precursor cells.
[0137] Acute lymphoblastic leukemia / lymphoblastic lymphoma (ALL / LBL) is defined as follows: ALL occurs when lymphoblastic cells infiltrate (>25%) into the bone marrow and appear in the peripheral blood; LBL occurs when they invade lymph nodes and extranodal organs. ALL includes both B-cell and T-cell forms, referred to as "B-cell acute lymphoblastic leukemia / lymphoblastic lymphoma" and "T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma," respectively. T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma includes the following (Swerdlow SH, et al (Editors). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017): T-lymphoblastic leukemia / lymphoma (Provisional entity: Early T-cell precursor lymphoblastic leukemia, Provisional entity).
[0138] Mature T-cell tumors include the following (Swerdlow SH, et al (Editors). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARCPress; 2017): T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, Systemic EBV positive T-cell lymphoma of childhood, Hydroa vacciniforme-like lymphoproliferative disorder, Adult T-cell leukemia / lymphoma, and Extranodal T-cell lymphoma.This list includes: nasal type, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the GI tract, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, mycosisfungoides, Sezary syndrome, primary cutaneous CD30 positive T-cell lymphoproliferative disorders, lymphomatoid papulosis, and primary cutaneous anaplastic large cell lymphoma. Primary cutaneous gamma-delta T-cell lymphoma, primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma, primary cutaneous acral CD8-positive T-cell lymphoma, primary cutaneous CD4-positive small / medium T-cell lymphoproliferative disorder, and peripheral T-cell lymphoma (nonspecific type).NOS, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, anaplastic large cell lymphoma (ALK positive), anaplastic large cell lymphoma (ALK negative), and breast implant-associated anaplastic large-cell lymphoma.
[0139] In this specification, "subjects in a state of T-cell dysfunction" refers to subjects whose T-cell effector function is reduced due to avoidance of immune surveillance, the formation of an immunosuppressive environment, or T-cell depletion caused by chronic infection or cancer, thus limiting the appropriate immune response against tumor cells. Subjects in a state of T-cell dysfunction include subjects in a state of T-cell apoptosis.
[0140] In this manual, "T-cell impotence" refers to a state in which T cells, as part of the immune system, are not activated and cannot function normally. Normally, T cells play a crucial role in triggering immune responses against foreign pathogens and substances, but in T-cell impotence, this response is suppressed. T-cell impotence is an important regulatory mechanism of the immune response, but excessive occurrence can lead to decreased immune function, potentially increasing the risk of tumor progression, infections, and other immune-related diseases. Therefore, when T-cell impotence occurs abnormally, it becomes a cause of immunodeficiency.
[0141] In this specification, "antigen-binding molecule" refers to a molecule that specifically binds to an epitope (antigen determinant), such as an antibody or antibody fragment. "Bispecific" means that the antigen-binding molecule specifically binds to two different antigen determinants. A bispecific antigen-binding molecule contains at least two antigen-binding moieties that bind to different antigen determinants.
[0142] The antibody exhibits a structure consisting of two heavy chains (H chains) and two light chains (L chains). These light and heavy chains are linked by disulfide bonds (SS bases) to form a heterodimer, and two of these heterodimers then combine to form a Y-shaped heterotetramer. Typically, the heavy chain includes a variable region (VH), constant regions (CH1, CH2, and CH3), and a hinge region located between CH1 and CH2. The light chain includes a variable region (VL) and a constant region (CL). The variable regions contain complementarity-determining regions (CDRs) and framework regions (FRs). Each of the light and heavy chain variable regions contains three CDRs (heavy chain CDRs 1–3 and light chain CDRs 1–3) and four FRs (heavy chain FRs 1–4 and light chain FRs 1–4). Methods for identifying CDRs are well-known, for example, the IMGT / V-QUEST search page (http: / / www.imgt.org / IMGT_vquest / input), Brochet, X. et al., Nucl. Acids Res. 36, W503-508 (2008), and references: Giudicelli, V., Brochet, X., Lefranc, M.-P., Cold Spring Harb Protoc.2011 Jun 1;2011(6). pii: pdb.prot5633. doi: 10.1101 / pdb.prot5633. PMID:21632778). In addition, any other means known in the field can be used as long as the same result can be obtained (Kabat et al., Sequence of Proteins of Immunological Interest (1987), National Institute of Health, Bethesda, Md.; Chothia et al., Nature (1989) 342:877).
[0143] In this specification, antibody fragments are antigen-binding antibody fragments. Examples of antibody fragments include Fab, F(ab')2, Fv, and scFv, but are not limited to these. Fab refers to an antibody fragment in which the VL-CL and VH-CH1 domains are linked by disulfide bonds. F(ab')2 refers to an antibody fragment in which two Fab fragments are linked by disulfide bonds in the hinge region. The Fv fragment contains VL and VH. scFv is a fusion protein in which VH and VL are linked by a linker peptide (approximately 10–25 amino acids in length).
[0144] The first embodiment of the present invention relates to a therapeutic agent for T-cell tumors in a subject with T-cell dysfunction, comprising a bispecific antigen-binding molecule. The bispecific antigen-binding molecule constituting the therapeutic agent of the present invention comprises: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors.
[0145] In this invention, the description of "a portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells" (hereinafter referred to as the tumor antigen-binding portion) refers to a polypeptide molecule that specifically binds to a target tumor antigen expressed in T-cell tumor cells. In one embodiment, the tumor antigen-binding portion can direct normal T cells to T-cell tumor cells expressing the target tumor antigen. The tumor antigen-binding portion comprises an antibody or a fragment thereof.
[0146] In this specification, "specific binding" means selective binding to a specific antigen, distinguishable from non-specific interactions. The binding ability of an antigen-binding molecule to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance (SPR) techniques. In specific embodiments, the antigen-binding molecule can bind to the target antigen with a dissociation constant (KD) of less than 1×10⁻⁵ M (mol / L), less than 5×10⁻⁶ M, less than 1×10⁻⁶ M, less than 5×10⁻⁷ M, less than 1×10⁻⁷ M, less than 5×10⁻⁸ M, less than 1×10⁻⁸ M, less than 5×10⁻⁹ M, less than 1×10⁻⁹ M, less than 5×10⁻¹⁰ M, or less than 1×10⁻¹⁰ M.
[0147] Preferably, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if present, the normal T cells are substantially not activated when the bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. The absence of the target tumor antigen expressed in T-cell tumor cells in normal T cells can be determined by flow cytometry analysis using fluorescently labeled antibodies that specifically bind to the target tumor antigen. The presence or absence of an antigen in normal T cells, or the positive or negative expression of an antigen in normal T cells, can be determined based on graphs obtained from flow cytometry analysis. Specific details of the flow cytometry analysis are described later. In a preferred embodiment, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, thereby allowing the bispecific antigen-binding molecule to appropriately bridge normal T cells and T-cell tumor cells (e.g., Figure 1B Furthermore, the statement that "normal T cells are not substantially activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen" can be achieved by creating a tumor antigen-binding moiety based on an antibody that does not have agonist activity. This is because it is believed that antibody-based agonist activity plays a significant role in the activation of normal T cells resulting from the binding of a bispecific antigen-binding molecule (e.g., an antibody) to the antigen.
[0148] CD3 is expressed in both normal T cells and T-cell tumor cells. Bispecific antibodies targeting CD3 and tumor antigens bind simultaneously to both the CD3 antigen expressed in T-cell malignancies and the target antigen expressed in T-cell malignancies, thus linking the malignant tumor cells together. Figure 1A Therefore, it is likely that the therapeutic effect of the bispecific antibody may not be fully obtained. In Example 14 described later, the cytotoxic activity of the bispecific antibody binding to CD3 and the tumor antigen against CD3-expressing tumor cell lines was reduced compared to the same activity against tumor cell lines that do not express CD3 (CD3 knockout tumor cell lines). This result suggests that CD3 expression in tumor cell lines weakens cytotoxic activity. In bispecific antigen-binding molecules used for T-cell tumors (most of which are CD3 positive), the target for effector T cell induction should be molecules other than CD3.
[0149] The target tumor antigen expressed in T-cell tumor cells is a different antigen from the target antigen expressed on the normal T-cell side. The bispecific antigen-binding molecule is preferably configured to bind to different antigens, and to bind to different types of antigens expressed on T-cell tumor cells or normal T cells respectively.
[0150] In a particular manner, it is preferred that the target tumor antigen expressed in T-cell tumor cells, even if present in normal T cells, is expressed in T-cell tumor cells at a higher frequency than in normal T cells. For example, for the target tumor antigen, the ratio of the number of molecules expressed in each T-cell tumor cell to the number of molecules expressed in each normal T cell is sufficient, preferably 120%, 130%, 140%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% or more. The number of molecules of the target tumor antigen expressed per cell can be determined by flow cytometry analysis using a fluorescently labeled antibody that specifically binds to the target tumor antigen. By expressing the target tumor antigen in T-cell tumor cells at a higher frequency than in normal T cells, the bispecific antigen-binding molecule can bridge a sufficient number of normal T cells with T-cell tumor cells, thereby achieving a therapeutic effect. Specific examples of target tumor antigens are described later.
[0151] In this invention, the treatment target is a subject suffering from any T-cell tumor, which can be a subject in a state of T-cell dysfunction. In a specific manner, the T-cell tumor in a subject in a state of T-cell dysfunction can be adult T-cell leukemia (ATL), peripheral T-cell lymphoma (PTCL), or T-cell acute lymphoblastic leukemia (TALL). Peripheral T-cell lymphoma (PTCL) is a general term for lymphomas originating from T cells that differentiate and mature in the thymus and migrate to peripheral organs. PTCL accounts for approximately 10% of all lymphomas in Japan. PTCL is classified into peripheral T-cell lymphoma nonspecific type (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK-positive anaplastic large cell lymphoma (ALCL), and ALK-negative ALCL. PTCL-NOS is difficult to distinguish from ATL (adult T-cell lymphoma) histopathologically, requiring screening with anti-HTLV-1 antibodies. In certain approaches, T-cell tumors in subjects with T-cell dysfunction are considered adult T-cell leukemia (ATL).
[0152] The state of T-cell dysfunction in a subject can be inferred by comparing the expression levels of immunosuppressive checkpoint molecules (immune exhaustion molecules) in T cells with those in normal T cells. Examples of immunosuppressive checkpoint molecules include PD-1, TIM-3, CTLA-4, LAG-3, and TIGIT, but are not limited to these. High expression of PD-1 has been reported to be associated with T-cell exhaustion, and the expression level of PD-1 is correlated with the degree of T-cell exhaustion (Wei F, et al. ProcNatl Acad Sci US A. 2013.). The expression levels of immunosuppressive checkpoint molecules in normal T cells can be, for example, the expression levels of immunosuppressive checkpoint molecules in normal individuals, the average expression levels of immunosuppressive checkpoint molecules in T cells from multiple normal individuals, or the expression levels of immunosuppressive checkpoint molecules in samples collected from the subject before they entered a state of T-cell dysfunction. The expression of immune checkpoint molecules can be determined, for example, by using fluorescently labeled antibodies and flow cytometry analysis.
[0153] In Examples 16 and 17 described later, under the condition of adding the bispecific antibody of the present invention, PBMCs collected from ATL patients with high PD-1 expression and suggested potential T-cell dysfunction showed the same or greater cytotoxic activity against tumor cells as PBMCs from healthy individuals. Therefore, it can be seen that some ATL patients are in a state of T-cell dysfunction, and the bispecific antibody of the present invention is considered to be able to induce cytotoxic activity even in patients with T-cell dysfunction.
[0154] Furthermore, if the subject is in a state of T cell dysfunction, this can be inferred by comparing the gene expression profiles of the subject's T cells with those of healthy individuals. For example, a comprehensive gene expression analysis (e.g., RNA-seq) can be performed on the subject's T cells. Based on the obtained expression data, the expressed genes of the T cells as a whole or specific subgroups such as CD8-positive T cells can be classified according to their biological functions (e.g., activation-related, cell cycle-related, pro-apoptosis-related, pro-survival-related, T cell exhaustion-related, and cytotoxicity-related gene groups). By comparing the expressed proteins in these functional categories with corresponding cells (T cells or the aforementioned specific subgroups) from healthy individuals, the functional state of the subject's T cells in the immune response can be inferred. A comprehensive gene expression analysis can be performed using either bulk RNA-seq analysis, which uses RNA obtained from T cell populations, or single-cell RNA-seq analysis, which obtains expression information at the single-cell level.
[0155] In Example 18, described later, single-cell RNA-seq analysis showed reduced expression of cytotoxicity-related gene clusters in CD8-positive T cells examined from two ATL patients. This was interpreted as suggesting that CD8-positive T cells were unable to exert cytotoxic activity against tumor cells, i.e., a state of limited anti-tumor immune response. In Example 19, described later, it was confirmed that the bispecific antibody of the present invention, which recognizes TRBCs, could induce cytotoxic activity even in PBMCs derived from patients in the T-cell dysfunctional state of Example 18.
[0156] <Antigen-binding portion on the normal T cell side> In this invention, the description of "a portion that specifically binds to an antigen having a subtype, which is a target antigen of a normal T cell" (hereinafter referred to as the normal T cell side antigen-binding portion) refers to a polypeptide molecule that specifically binds to a target antigen expressed in normal T cells. The normal T cell side antigen-binding portion comprises an antibody or a fragment thereof. In one embodiment, the normal T cell side antigen-binding portion can activate TCR signal transduction (T cell activation) via a normal T cell side target antigen. Further, it is preferable that it can induce cellular responses such as cytokine production or cytotoxic activity in T cells.
[0157] "Antigen with subtypes" refers to substances that, among the materials constituting T cells (e.g., peptides, proteins, sugars, lipids, or other organic or inorganic substances), have variants with the same or substantially the same function but different structures (e.g., amino acid sequence, stereostructure of peptides and proteins, building blocks and types of sugars, arrangement and types of lipid building elements). Each variant is called a subtype. In one approach, it is preferable that each T cell expresses only one of the subtypes of "antigen with subtypes". In one example, "antigen with subtypes" may be an antigen with TCR diversity based on somatic recombination (also known as "V(D)J gene rearrangement"), but is not limited to this. Most T cell receptors consist of an α chain and a β chain. The TCR α chain and β chain include a variable region at the N-terminus and a constant region at the C-terminus. TCR diversity arises from somatic recombination caused by the selection of the variable region (V), the diverse region (D), the linker region (J), and the constant region (C) by each TCR chain. The V, D, and J gene fragments are contained in the β chain, and the V and J gene fragments are contained in the α chain. For example, one of the 30 TRBV polypeptides generated through V(D)J gene rearrangement and allele elimination is expressed on all T cells (WO2022 / 119955). TRBV polypeptides are examples of antigens with 30 subtypes. However, "subtyped antigens" refers to antigens expressed at any location on T cells, not just those present on the TCR.
[0158] There is no particular limitation on the number of subtypes of the "subtyped antigen" as long as it has two or more subtypes. When the number of subtypes is large, the number of normal T cells that can bind to the target antigen via the antigen-binding portion of the bispecific antigen-binding molecule on the normal T cell side is small, which may sometimes fail to provide a sufficient number of activated T cells required for the treatment of T-cell tumors. In one embodiment, the number of subtypes of the "subtyped antigen" may be, for example, 50 or less, preferably 40 or less, 30 or less, 20 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, or 3 or less, or 2.
[0159] A normal T cell population contains normal T cells expressing any of the subtypes of an antigen that serves as a target antigen for normal T cells. For example, when the number of subtypes of the antigen is three (subtypes A, B, and C), the normal T cell population contains cells expressing subtype A, cells expressing subtype B, and cells expressing subtype C. Even in T cell tumor cells, any of the aforementioned subtypes is usually expressed (e.g., any of subtypes A through C). The normal T cell-side antigen-binding portion of a bispecific antigen-binding molecule is configured to specifically bind to a subtype different from the subtype expressed in the T cell tumor cells. For example, when the subtype expressed in the T cell tumor cells is subtype A, the normal T cell-side antigen-binding portion of the bispecific antigen-binding molecule is configured to specifically bind to subtype B or subtype C. The tumor antigen-binding portion of a bispecific antigen-binding molecule is configured to specifically bind to an antigen that is different from a subtype of an antigen that serves as a target antigen for normal T cells and is expressed at a high frequency in T-cell tumor cells. In this way, the bispecific antigen-binding molecule can appropriately bridge the gap between normal T cells and T-cell tumor cells.
[0160] In this invention, normal T cells are preferably activated by binding a bispecific antigen-binding molecule to a target antigen on the normal T cell side. T cell activation can be evaluated, for example, by culturing T cells in the presence of IL-2 and the normal T cell side antigen-binding portion of the bispecific antigen-binding molecule, as described in the reference examples below, and by observing or measuring cell phenotype, T cell activation markers, cell proliferation, cell viability, and the amount of secreted cytokines.
[0161] In this invention, to provide a sufficient number of activated T cells required for the treatment of T-cell tumors, it is preferable to have a sufficient proportion of normal T-cell target antigen subtypes. The normal T-cell target antigen subtypes are preferably expressed in at least 25% of the total number of normal T-cell cells, more preferably in at least 30%, 40%, or 50%. When selecting "antigens with subtypes," the proportion of normal T-cell target antigen subtypes can be based on human averages or on analytical values from patients being treated. In one embodiment, to provide a sufficient number of activated T cells required for the treatment of T-cell tumors, the blood concentration of cells expressing normal T-cell target antigen subtypes can be at least 50 cells / μL, preferably at least 100 cells / μL, 200 cells / μL, or 300 cells / μL. Furthermore, the "antigens with subtypes" are not antigens present in γδ T cells, but preferably in αβ T cells. This is because γδT cells constitute only a few percent of the total number of T cells, thus failing to mobilize a sufficient number of T cells to kill tumor cells and achieve therapeutic effects.
[0162] In one approach, the subtype of the normal T cell side target antigen is any subtype of antigen that is not expressed in T cell tumor cells. For example, a population of clonal proliferating T cell tumor cells may have any subtype, so the normal T cell side target antigen, as a bispecific antigen-binding molecule, may select a subtype that is different from the subtype expressed in the T cell tumor cell population.
[0163] In one approach, the normal T cell side target antigen not expressed in tumor cells is a subtype of the normal T cell side target antigen that is not expressed in T cell tumor cells, which is any subtype of the antigen subtype.
[0164] In one approach, the subtype of the target antigen for normal T cells is TRBC (T cell receptor β constant region). The subtype expressed in T cell tumor cells is TRBC1, and the subtype of the target antigen for normal T cells is TRBC2. That is, in the study, the subtype of TRBC expressed in T cell tumor cells is analyzed. If it is TRBC1, then the target antigen for normal T cells using the bispecific antigen-binding molecule can be designated as TRBC2. In this way, normal T cells can be mobilized as effector cells using the bispecific antigen-binding molecule.
[0165] In a further embodiment, the subtype of the target antigen for normal T cells is TRBC, the subtype expressed in T-cell tumor cells is TRBC2, and the subtype of the target antigen for normal T cells is TRBC1. That is, in the study, the subtype of TRBC expressed in T-cell tumor cells is analyzed; if it is TRBC2, then the target antigen for normal T cells using the bispecific antigen-binding molecule can be designated as TRBC1. In this way, normal T cells can be mobilized as effector cells using the bispecific antigen-binding molecule.
[0166] In a further embodiment, the subtype of the target antigen for normal T cells is TRBC, the T-cell tumor cells are TRBC1-negative and TRBC2-negative, and the subtype of the normal T-cell target antigen is either TRBC1 or TRBC2. That is, in the subject, the subtype of TRBC expressed in T-cell tumor cells is analyzed; if it is TRBC1-negative and TRBC2-negative, then the normal T-cell target antigen of the bispecific antigen-binding molecule can be either TRBC1 or TRBC2. In this case, neither TRBC1 nor TRBC2 is expressed in T-cell tumor cells, but either is expressed in normal T cells. Therefore, through the action of a bispecific antigen-binding molecule having a normal T-cell target antigen-binding portion that binds to either TRBC1 or TRBC2, normal T cells can be mobilized as effector cells.
[0167] In this specification, TRBC1 and TRBC2 refer to two functionally identical proteins in the constant region of the TCR β chain. T cell receptors (TCRs) are antigen receptor molecules expressed on T cells that recognize antigens that bind to the major histocompatibility gene complex (MHC) molecule. Two functionally identical genes exist at the locus (Chr7:q34) in the constant region of the TCR β chain (TRBC1 (Gene ID: 28639) and TRBC2 (Gene ID: 28636)). The mature proteins of TRBC1 and TRBC2 differ by only four amino acid residues. The amino acid sequences of TCRs containing TRBC1 and TRBC2 (TRBC1-TCR and TRBC2-TCR) are largely identical; however, they can still be distinguished by antibodies (Maciocia PM, et al., ibid.). In addition, approximately 35% of TRBC1-positive cells and 65% of TRBC2-positive cells are present in peripheral blood T cells of normal individuals, and the monoclonal nature of TRBCs has been confirmed in many types of T-cell malignancies by flow cytometry and immunohistochemistry (IHC) (Maciocia PM, et al., ibid.).
[0168] It has been reported that in normal T cell populations, cells expressing TRBC1 and those expressing TRBC2 coexist, but in the overall population of T cell tumor cells, either TRBC1 or TRBC2 is expressed exclusively (Maciocia PM, et al., ibid.). Therefore, the use of TRBC1 or TRBC2 as target antigens on the tumor cell side has been proposed (Japanese Patent No. 6767872 (Japanese Patent Application 2016-554603)). However, it was previously unknown to use TRBC subtypes different from those expressed in tumor cells as target antigens on the normal T cell side or effector cell side.
[0169] In a particular manner, the therapeutic agent for T-cell tumors of a subject in a state of T-cell dysfunction according to the present invention comprises a bispecific antigen-binding molecule, the bispecific antigen-binding molecule comprising: At least one portion of the target tumor antigen specifically binds to T-cell tumor cells expressed in tumor cells, and At least one portion of the substance specifically binds to either TRBC1 or TRBC2 expressed in normal T cells.
[0170] In this invention, the description of "a portion that specifically binds to TRBC1 or TRBC2 expressed in normal T cells" (hereinafter referred to as the TRBC1 or TRBC2 binding portion) refers to a polypeptide molecule that specifically binds to TRBC1 or TRBC2 expressed in normal T cells. The TRBC1 or TRBC2 binding portion contains an antibody or a fragment thereof. In one embodiment, the TRBC1 or TRBC2 binding portion can activate TCR signal transduction (T cell activation) via TRBC1 or TRBC2. Further, it is preferable to induce cellular responses such as cytokine production or cytotoxic activity of T cells.
[0171] Bispecific antigen-binding molecules preferably bind simultaneously to TRBC1 or TRBC2 expressed in normal T cells and target tumor antigens expressed in T cell tumor cells.
[0172] In one approach, when T-cell tumor cells are TRBC1 positive, the aforementioned bispecific antigen-binding molecule includes at least one portion that specifically binds to TRBC2 expressed in normal T cells; when T-cell tumor cells are TRBC2 positive, the aforementioned bispecific antigen-binding molecule includes at least one portion that specifically binds to TRBC1 expressed in normal T cells. By using TRBCs of different subtypes than those expressed in T-cell tumor cells as targets on the effector cell (T lymphocyte) side (when tumor cells express TRBC1, the effector cell target is set to TRBC2; when tumor cells express TRBC2, the effector cell target is set to TRBC1), it is impossible to cause T-cell dysfunction and high therapeutic efficacy can be achieved.
[0173] In the examples described later, compared to the cytotoxic activity against TRBC2-positive tumor cell lines, the bispecific antibody with the normal T cell side antigen-binding moiety binding to TRBC2 showed higher cytotoxic activity against TRBC1-positive tumor cell lines (Example 14). Compared to TRBC2-positive tumor cell lines, the bispecific antibody with the normal T cell side antigen-binding moiety binding to TRBC1 showed high cytotoxic activity (Example 4). These findings confirm that, for the treatment of tumors, bispecific antibodies that recognize and express different subtypes of TRBC in T cell tumor cells via the normal T cell side antigen-binding moiety can achieve high cytotoxic activity.
[0174] In this invention, "TRBC1 positive" in T-cell tumor cells can be understood as meaning that the T-cell tumor cells are "TRBC2 negative". Furthermore, in this invention, "TRBC2 positive" in T-cell tumor cells can be understood as meaning that the T-cell tumor cells are "TRBC1 negative". It has been reported that normal T-cell populations contain a mixture of cells expressing TRBC1 and cells expressing TRBC2, but in the overall T-cell tumor cell population, either TRBC1 or TRBC2 is expressed exclusively (Maciocia PM, et al., ibid.).
[0175] In one approach, there may be cases where the T-cell tumor cells are TRBC1-negative and TRBC2-negative. When the T-cell tumor cells are TRBC1-negative and TRBC2-negative, the normal T-cell side target antigen of the aforementioned bispecific antigen-binding molecule can be either TRBC1 or TRBC2, that is, it can include either a portion that specifically binds to TRBC1 expressed in normal T cells or a portion that specifically binds to TRBC2 expressed in normal T cells.
[0176] In one approach, the target tumor antigen is not either TRBC1 or TRBC2. That is, at least one portion of the aforementioned target tumor antigen specifically binding to expressed in T-cell tumor cells is designed to specifically bind to antigens other than TRBC1 and TRBC2, and therefore does not bind to or substantially does not bind to either TRBC1 or TRBC2.
[0177] In cases of TRBC1-positive T-cell malignancies, TRBC1 is designated as the target antigen for tumor cells; in cases of TRBC2-positive malignancies, TRBC2 is designated as the target antigen for tumor cells. For example, the use of chimeric antigen receptors (CARs) containing an antigen-binding domain that selectively binds to either TRBC1 or TRBC2 has been proposed for the treatment of T-cell lymphomas or leukemia (Maciocia PM, et al., ibid., Japanese Patent No. 6767872 (Japanese Patent Application 2016-554603)). However, CAR-T cells using TRBC1 antibodies kill not only TRBC1-positive cancer cells but also TRBC1-positive T lymphocytes. Approximately 50% of T lymphocytes may die, potentially leading to T-cell immunodeficiency. In this invention, a bispecific antigen-binding molecule is used to target tumor cells with antigens other than TRBC expressed in T-cell malignancies, and to target effector cells (T lymphocytes) with TRBC subtypes different from those expressed in T-cell malignancies. This induces normal T cells to kill tumor cells, thus reducing the likelihood of T-cell immunodeficiency.
[0178] T-cell tumor cells have been reported to exclusively express either TRBC1 or TRBC2 in their overall cell population. However, it is also possible for T-cell tumor cells to not express either TRBC1 or TRBC2. For example, this can occur in cases of malignant transformation of T cells that do not express TCR. The present invention can treat T-cell tumors even when neither TRBC1 nor TRBC2 is expressed in T-cell tumor cells. This is because normal T cells express either TRBC1 or TRBC2; therefore, by using a bispecific antigen-binding molecule that targets either TRBC1 or TRBC2 as a T-cell-side target antigen and then targets antigens other than TRBCs expressed in T-cell tumor cells as tumor-side targets, approximately half of the normal T-cell population can be induced to kill T-cell tumor cells.
[0179] In the examples described later, bispecific antibodies that bind to TRBC1 and TRBC2 at the normal T cell side antigen binding site, respectively, and bispecific antibodies that bind to TRBC2 at the normal T cell side antigen binding site, respectively, showed cytotoxic activity relative to tumor cell lines that do not express either TRBC1 or TRBC2 (Examples 3 and 5).
[0180] Cells that are TRBC1 positive or negative can be determined by flow cytometry analysis using fluorescently labeled antibodies that specifically bind to TRBC1. Examples of antibodies that specifically bind to TRBC1 include, for example, the JOVI-1 clone (US10730942, protein-based T-cell receptor knockdown SEQ ID No. 15, SEQ ID No. 16). Similarly, T cells that are TRBC2 positive or negative can be determined by flow cytometry analysis using fluorescently labeled antibodies that specifically bind to TRBC2. Examples of antibodies that specifically bind to TRBC2 include, for example, the various antibodies described in WO2020 / 089644.
[0181] Whether the expression of a cellular antigen is positive or negative can be determined based on graphs obtained from flow cytometry analysis. The position of the antigen on the graph can vary depending on the machine's voltage settings, sensitivity settings, antibody clones used, staining conditions, and pigments used, but those skilled in the art can appropriately draw lines on the resulting graph without cutting into the observed cell population. In determining whether the expression of a target cellular antigen is positive or negative, the use of an isotype control antibody as a negative control can be used. An isotype control antibody is an antibody that does not react with a specific antigen. Typically, in experiments using antibodies, background may occur due to non-specific binding to proteins other than the target and binding to Fc receptors on the cell surface. By comparing with a system using an antibody as a negative control, it can be determined whether the antibody's response to the target antigen is specific. Furthermore, the influence of background can be eliminated, and the signal intensity can be correctly interpreted.
[0182] <TRBC1 junction> The bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may include a TRBC1 binding portion and a tumor antigen binding portion. The TRBC1 binding portion may be the anti-TRBC1 antibody described in US Patent No. 10730942 (US10730942 protein-based T-cell receptor knockdown SEQ ID No. 15, SEQ ID No. 16), or it may be the humanized anti-TRBC1 antibody described in Japanese Patent No. 7177794 (corresponding to WO2018 / 224844) (SEQ ID NO: 9 and 19 of Japanese Patent No. 7177794).
[0183] In one embodiment, the bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC1 expressed in normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:15.
[0184] In a specific manner, at least one portion specifically binding to TRBC1 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5. In a further specific manner, at least one portion specifically binding to TRBC1 expressed in normal T cells comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:4, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:5. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:4 or 5 may be present in the complementarity-determining region (CDR) or frame (FR).
[0185] In a specific manner, at least one portion specifically binding to TRBC1 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149. In a further specific manner, at least one portion specifically binding to TRBC1 expressed in normal T cells comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:148, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:149. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:148 or 149 may be present in the complementarity-determining region (CDR) or frame (FR).
[0186] In this specification, the "amino acid sequence identity percentage (%)" associated with the reference polypeptide sequence is defined as: the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues of the reference polypeptide, after sequence alignment and, if necessary, introducing gaps to obtain the maximum sequence identity percentage, without considering any conservative substitutions as part of sequence identity. Alignment used to determine the amino acid sequence identity percentage can be performed using various methods within the skill scope of those skilled in the art, such as publicly available computer software like BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for sequence alignment, including any algorithm required to achieve maximum alignment for the full length of the sequence to be compared.
[0187] In certain approaches, to improve the binding affinity and / or other biological properties of the TRBC1 binding moiety, amino acid sequence variants of bispecific antigen-binding molecules containing the TRBC1 binding moiety are created. These amino acid sequence variants can be created by introducing suitable mutations (deletions, insertions, and substitutions) into the nucleotide sequence encoding an anti-TRBC1 antibody or through peptide synthesis. Mutations can be introduced into the antibody's complementarity-determining region (CDR) or frame (FR), depending on the property to be improved. For the amino acid sequence variants, selection is performed for preservation or improvement of binding affinity, preservation or improvement of antigen specificity, reduction of immunogenicity, etc.
[0188] <TRBC2 junction> The bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may include a TRBC2 binding portion and a tumor antigen-binding portion. The TRBC2 binding portion may be various anti-TRBC2 antibodies described in WO2020 / 089644, or an antigen-binding domain that binds to TRBC2. The TRBC2 binding portion may also include the VH domain of hJOVI-1 of WO2020 / 089644 (SEQ ID NO:1 of WO2020 / 089644) having three amino acid substitutions for T28K, Y32F, and A100N (Table 1 (page 23) of WO2020 / 089644) and the VL domain of hJOVI-1 (SEQ ID NO:2 of WO2020 / 089644).
[0189] In one embodiment, the bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC2 expressed in normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21.
[0190] In a particular manner, at least one portion specifically binding to TRBC2 expressed in normal T cells comprises: a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7. In a further particular manner, at least one portion specifically binding to TRBC2 expressed in normal T cells comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:6, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:7. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:6 or 7 may be present in the complementarity-determining region (CDR) or frame (FR).
[0191] In certain approaches, to improve the binding affinity and / or other biological properties of the TRBC1 binding moiety, amino acid sequence variants of bispecific antigen-binding molecules containing the TRBC1 binding moiety are created. These amino acid sequence variants can be created, for example, by introducing suitable mutations (deletions, insertions, and substitutions) into the nucleotide sequence encoding an anti-TRBC2 antibody or through peptide synthesis. Mutations can be introduced into the antibody's complementarity-determining region (CDR) or frame (FR), depending on the property to be improved. For the amino acid sequence variants, selection is performed for preservation or improvement of binding affinity, preservation or improvement of antigen specificity, reduction of immunogenicity, etc.
[0192] In a particular manner, at least one portion that specifically binds to TRBC1 or TRBC2 expressed in normal T cells may be an scFv or Fab fragment.
[0193] The table below shows the CDR sequences of the TRBC1 or TRBC2 antigen binding sites.
[0194] [Table 1]
[0195] <Tumor Antigen Binding Part> The bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may include a TRBC1 or TRBC2 binding portion and a tumor antigen-binding portion. The tumor antigen, as the target of the present invention, is an antigen expressed in T-cell tumor cells. Most antigens expressed in T-cell tumor cells are well-known in the art and can be used as target tumor antigens in the present invention. Examples of target tumor antigens are described in other parts of this application. The tumor antigen-binding portion can be made based on known antibodies. Most antibodies for T-cell tumor antigens are well-known in the art and can be used in the present invention. Those skilled in the art can select suitable light chain variable regions and heavy chain variable regions from the amino acid sequence information of known antibodies and construct bispecific antibodies using genetic engineering methods. In genetic engineering methods, the gene sequence encoding the antibody can be inserted into an expression vector, transformed into a host cell, and then the host cell can be cultured to produce an antibody. Examples of Fc domains, peptide linkers, and antibody forms that can be used in the constructed bispecific antibodies are described in other parts of this application. Non-human antibodies (e.g., mouse antibodies) can be humanized for the production of bispecific antibodies. Humanization methods are well-known, for example, by transplanting a non-human antibody's CDR into a human FR. Generally, when transplanting mouse CDRs into human FRs, selecting human FRs with high identity to the mouse FRs is considered advantageous in maintaining CDR function.
[0196] When the specific monoclonal antibody binding to the target tumor antigen is unknown, hybridoma and phage display methods can be used to create bispecific antigen-binding molecules. In the hybridoma method, B cells collected from the spleen or lymph nodes of animals immunized with a peptide of the target tumor antigen, particularly rats or mice, are fused with myeloma cells to create a hybridoma. Hybridomas that generate antibodies that react with the antigen are selected, and monoclonal antibodies can be generated using the selected hybridomas. Phage display is a technique that uses a library of antibody variable regions functionally presented on a phage to select antibodies with affinity for the target molecule. The genes of the antibodies contained within the phage can be sequenced, and monoclonal antibodies can be created based on their sequence information.
[0197] In one embodiment, the tumor antigens targeted by the present invention are not pan-T cell antigens such as CD2, CD3, CD5, and CD7. This is because they would lead to T cell depletion, potentially resulting in clinically unacceptable levels of immunodeficiency. In another embodiment, when the TRBC1 binding portion is used as the normal T cell-side antigen-binding portion of the bispecific antibody of the present invention, the tumor antigen targeted by the present invention is not TRBC1; or when the TRBC2 binding portion is used as the normal T cell-side antigen-binding portion of the bispecific antibody of the present invention, the tumor antigen targeted by the present invention is not TRBC2. This is because these would lead to the depletion of normal T cells, potentially resulting in clinically unacceptable levels of immunodeficiency. For example, WO2022 / 177889A1 discloses a method that induces fratricide in normal TRBC1-positive T cells, causing their death, by binding a bispecific antibody to both normal TRBC1-positive T cells and TRBC1-positive cancer cells.
[0198] (Target tumor antigen) In this invention, examples of target tumor antigens expressed in T-cell tumor cells include, but are not limited to, the following T-cell antigens: CD4, CD8, CD13, CD16, CD17, CD18, CD19, CD20, CD21, CD23, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32b, CD35, CD37, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49, CD49b, CD49c, CD49d, CD49e, CD49f. CD50, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD62L, CD63, CD68, CD69, CD70, CD71, CD73, CD74, CD75S, CD80, CD81, CD82, CD84, CD85A, CD85J, CD86, CD87, CD92, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD101, CD102, CD103, CD107a, CD107b, CD108, CD109, CD119, CD120a, CD120 b. CD121a, CD121b, CD122, CD124, CD126, CD127, CD128, CD129, CD130, CD132, CD134, CD137, CD146, CD147, CD148, CD150, CD152, CD153, CD40L (CD154) , CD156b, CD158a, CD158b1, CD158b2, CD158e1 / e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, CD160, CD161, CD162, CD164, CD172g, CD1 78. CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CDw199, CD205, CD210a, CDw210b, CD212, CD2 15. CD217, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD229, CD230, CD231, CD244, CD245, CD246, CD247, CD253, CD254,CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267, CD268, CD270 , CD272, CD273, CD274, CD275, CD277, CD278, CD279, CD283, CD288, CD289, CD290, CD294, CD295 , CD296, CD298, CD300a, CD300c, CD300e, CD305, CD306, CD307c, CD314, CD316, CD317, CD319, CD321, CD328, CD351, CD352, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362, CD363. ,
[0199] In one approach, the target tumor antigen expressed in T-cell tumor cells may be selected from, but is not limited to, CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4, CXCR7, TIGIT, CADM1, GPR15, CXCR5, CXCL13, SLAM, ICOS, CD134, CXCR3, anaplastic lymphoma kinase, CD30, ST2(L), CCR5, Notch1, CD38, CD1a, CCR9 (CD199), CD47, IL-7Rα (CD127), and CD40L (CD154).
[0200] CCR1 (CC chemokine receptor 1), CCR4, CCR5, CCR7, CCR8, CCR9 (CD199), CCR10, CXCR (CXC chemokine receptor) 3, CXCR4, CXCR5 and CXCR7 are chemokine receptors. CCR1 is also known as CD191.
[0201] CXCL13 (CXC chemokine ligand 13) is a chemokine ligand.
[0202] TIGIT (a T-cell immune receptor with Ig and ITIM domains) is an immune checkpoint receptor found in NK cells, cytotoxic T cells, memory T cells, and control T cells (Tregs).
[0203] CADM1 (cell adhesion molecule 1) is an intercellular adhesion molecule belonging to the immunoglobulin superfamily cell adhesion molecule group (IgCAM).
[0204] GPR15 (G protein-coupled receptor 15) is a class A orphan G protein conjugate receptor that is expressed in epithelial cells, synovial macrophages, endothelial cells, lymphocytes, and especially T cells.
[0205] SLAM (signaling lymphocyte activating molecules) is a family of signal transduction lymphocyte activating molecules (SLAM).
[0206] ICOS (Inducible T-cell Co-stimulatory Molecule) is a 55-60 kDa disulfide homodimer T-cell surface glycoprotein, also known as CD278.
[0207] CD134 is a member of the tumor necrosis factor receptor (TNFR) superfamily.
[0208] Anaplastic lymphoma kinase (ALK) is a 220 kDa transmembrane glycoprotein, also known as CD246, that is primarily expressed in the developing nervous system.
[0209] CD30 is a membrane-bound glycoprotein with a molecular weight of 105-120kD belonging to the TNF receptor superfamily. It is strongly expressed in monocyte Hodgkin cells and multinucleated Reed-Sternberg cells of Hodgkin lymphoma, as well as in tumor cells of anaplastic large cell lymphoma (ALCL).
[0210] ST2(L) is the product of the ST2 gene, which exists in secretory form (ST2) and transmembrane receptor form (ST2L). The ST2 gene has been cloned to be specifically expressed during the initiation of cell proliferation.
[0211] Notch1 is a member of the Notch family.
[0212] CD38 is also known as cyclic ADP-ribolytic enzyme. CD1a is a CD1 isoform. There are four CD1 isoforms in humans (CD1a, CD1b, CD1c, and CD1d). CD1a is a lipid-presenting molecule whose expression is essentially limited in cortical / thymic T-cell acute lymphoblastic leukemia (cortical T-ALL) and Langerhans cell (LC) histiocytosis, and is practically absent in human tissues except for developing cortical thymocytes and LC (Blood. 2019;133(21):2291-2304).
[0213] CD47 is also known as an integrin-associated protein (IAP).
[0214] IL-7Rα (CD127) is mainly expressed in thymocytes, dendritic cells, monocytes, and mature T cells. IL-7R is a heterodimer of the α chain (CD127) and the common γ chain (γc chain) of the type I cytokine receptor.
[0215] CD40L (CD40 ligand, CD154) is a ligand protein belonging to the TNF superfamily, primarily expressed in activated CD4+ T cells. The CD40 / CD40L system suggests involvement in tumorigenesis.
[0216] CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4, CXCR7, TIGIT, CADM1, and GPR15 are potential target antigens for ATL treatment because they are expressed in adult T-cell leukemia (ATL) cells (Leukemia & Lymphoma, 2006; 47(10): 2163-2173).
[0217] CXCR5, CXCL13, SLAM, ICOS, CD134, and CXCR3 are expressed in angioimmunoblastic T-cell lymphoma (AITL) cells, and therefore can be used as target antigens for AITL treatment (Blood. 2004;103:236-241).
[0218] Anaplastic lymphoma kinase, CD30, ST2(L), and CCR5 are expressed in anaplastic large cell lymphoma cells and can therefore be used as target antigens for the treatment of peripheral T-cell lymphoma (PTCL), including anaplastic large cell lymphoma (Blood. 2004;103:236-241).
[0219] Notch1, CXCR4, CD38, CD1a, CCR9 (CD199), CD47, IL-7Rα (CD127), and CD40L (CD154) are expressed in T-cell acute lymphoblastic leukemia (TALL) cells, and therefore can be target antigens for TALL treatment (CD1a reference Blood. 2019;133(21):2291-2304, L-7Ralpha reference Blood 2021;138(12):1040-1052, CCR9 (CD199) reference Blood. 2022; 140(1): 25-37, CD38 and CD47 reference Blood 2022; 140(1): 45-57, Notch1, CXCR4, and CD38 reference Blood Cancer Discov 2021;2:19-31). (CCR4 binding portion) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CCR4. Therefore, the bispecific antigen-binding molecule may comprise a CCR4 binding portion and a TRBC1 binding portion, or it may comprise a CCR4 binding portion and a TRBC2 binding portion. The CCR4 binding portion may be the anti-CCR4 antibody mogliflozinumab described in Japanese Patent No. 4052515.
[0220] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CCR4, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:22 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:23, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:24 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:25 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:26 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:27.
[0221] In a particular embodiment, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:8 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:9. In a further particular embodiment, at least one portion specifically binding to CCR4 comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:8, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:9. Amino acid mutations (deletions, insertions, and substitutions) in the amino acid sequence of SEQ ID NO:8 or 9 may be present in the complementarity-determining region (CDR) or frame (FR).
[0222] In a particular manner, at least one portion that specifically binds to CCR4 can be an scFv or Fab fragment.
[0223] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:22 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:23, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:24 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:25 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:26 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:27.
[0224] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7. as well as At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:8 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:9.
[0225] (CD1a binding part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CD1a. Therefore, the bispecific antigen-binding molecule may comprise a CD1a-binding portion and a TRBC1-binding portion, or it may comprise a CD1a-binding portion and a TRBC2-binding portion. The CD1a-binding portion may be the anti-CD1a antibody SC02-113 described in WO2005 / 063819.
[0226] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CD1a, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:34 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:35, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:36 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:37 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:38 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:39.
[0227] In a particular embodiment, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:40 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:41. In a further particular embodiment, at least one portion specifically binding to CD1a comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:40, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:41. Amino acid mutations (deletions, insertions, and substitutions) in the amino acid sequence of SEQ ID NO:40 or 41 may be present in the complementarity-determining region (CDR) or frame (FR).
[0228] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:34 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:35, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:36 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:37 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:38 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:39.
[0229] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:41 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:42.
[0230] (CCR9 binding part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CCR9. Therefore, the bispecific antigen-binding molecule may comprise a CCR9 binding portion and a TRBC1 binding portion, or it may comprise a CCR9 binding portion and a TRBC2 binding portion. The CCR9 binding portion may be the anti-CCR9 antibody 9G7 described in WO2023 / 037125.
[0231] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CCR9, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:101 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:102, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:103 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:104 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:105, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:106.
[0232] In a specific manner, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:131 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:132. In a further specific manner, at least one portion specifically binding to CCR9 comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:131, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:132. Amino acid mutations (deletions, insertions, and substitutions) in the amino acid sequence of SEQ ID NO:131 or 132 may be present in the complementarity-determining region (CDR) or frame (FR).
[0233] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:101 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:102, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:103 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:104 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:105, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:106.
[0234] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:131 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:132.
[0235] (CXCR4 combination part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CXCR4. Therefore, the bispecific antigen-binding molecule may comprise a CXCR4 binding portion and a TRBC1 binding portion, or it may comprise a CXCR4 binding portion and a TRBC2 binding portion. The CXCR4 binding portion may be the anti-CXCR4 antibody (hz515H7 VH1 D76N-VL2) described in WO2010 / 125162.
[0236] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CXCR4, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:107 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:108, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:109 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:110 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:111 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:112.
[0237] In a particular embodiment, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:133 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:134. In a further particular embodiment, at least one portion specifically binding to CXCR4 comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:133, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:134. Amino acid mutations (deletions, insertions, and substitutions) in the amino acid sequence of SEQ ID NO:133 or 134 may be present in the complementarity-determining region (CDR) or frame (FR).
[0238] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:107 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:108, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:109 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:110 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:111 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:112.
[0239] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:133 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:134.
[0240] (TIGIT integration section) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be TIGIT. Therefore, the bispecific antigen-binding molecule may comprise a TIGIT-binding portion and a TRBC1-binding portion, or it may comprise a TIGIT-binding portion and a TRBC2-binding portion. The TIGIT-binding portion may be the anti-TIGIT antibody vibostolimab described in WO2016 / 028656.
[0241] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to TIGIT, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:89 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:90, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:91 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:92 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:93 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:94.
[0242] In a particular embodiment, at least one portion specifically binding to TIGIT comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:135 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:136. In a further particular embodiment, at least one portion specifically binding to TIGIT comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:135, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:136. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:135 or 136 may be present in the complementarity-determining region (CDR) or frame (FR).
[0243] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:89 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:90, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:91 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:92 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:93 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:94.
[0244] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:135 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:136.
[0245] (CCR8 binding part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CCR8. Therefore, the bispecific antigen-binding molecule may comprise a CCR8 binding portion and a TRBC1 binding portion, or it may comprise a CCR8 binding portion and a TRBC2 binding portion. The CCR8 binding portion may be the anti-CCR8 antibody ABBV-514 described in WO2023 / 010054.
[0246] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CCR8, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:95 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:96, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:97 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:98 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:99 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:100.
[0247] In a specific embodiment, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:137 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:138. In a further specific embodiment, at least one portion specifically binding to CCR8 comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:137, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:138. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:137 or 138 may be present in the complementarity-determining region (CDR) or frame (FR).
[0248] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:95 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:96, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:97 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:98 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:99 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:100.
[0249] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion that specifically binds to TRBC1 or TRBC2 expressed in normal T cells: (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:137 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:138.
[0250] (CD30 combination part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CD30. Therefore, the bispecific antigen-binding molecule may comprise a CD30-binding portion and a TRBC1-binding portion, or it may comprise a CD30-binding portion and a TRBC2-binding portion. The CD30-binding portion may be the anti-CD30 antibody AC10 described in Japanese Patent No. 4303964.
[0251] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CD30, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:113 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:114, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:115 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:116 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:117 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:118.
[0252] In a specific manner, at least one portion specifically binding to CCR4 comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:139 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:140. In a further specific manner, at least one portion specifically binding to CD30 comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:139, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:140. Amino acid mutations (deletions, insertions, and substitutions) targeting the amino acid sequence of SEQ ID NO:139 or 140 may be present in the complementarity-determining region (CDR) or frame (FR).
[0253] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:113 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:114, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:115 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:116 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:117 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:118.
[0254] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:139 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:140.
[0255] (CD40L assembly part) The target tumor antigen of the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment of the present invention may be CD40L (CD154). Therefore, the bispecific antigen-binding molecule may comprise a CD40L binding portion and a TRBC1 binding portion, or it may comprise a CD40L binding portion and a TRBC2 binding portion. The CD40L binding portion may be the anti-CD40L (CD154) antibody ABI793 described in Japanese Patent Application Publication No. 2003-526371 (WO01 / 068860).
[0256] In one embodiment, the bispecific antigen-binding molecule comprises a bispecific antigen-binding molecule containing at least one portion that specifically binds to CD40L (CD154), wherein the aforementioned at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:119 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:120, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:121 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:122 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:123 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:124.
[0257] In a particular embodiment, at least one portion specifically binding to CD40L (CD154) comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:141 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:142. In a further particular embodiment, at least one portion specifically binding to CD40L (CD154) comprises: a heavy chain variable region VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:141, and a light chain variable region VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence described in SEQ ID NO:142. Amino acid mutations (deletions, insertions, and substitutions) in the amino acid sequence of SEQ ID NO:141 or 142 can be present in the complementarity-determining region (CDR) or frame (FR).
[0258] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 containing the amino acid sequence described in SEQ ID NO:15, or (b) Contains the VH and VL structural domains. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:21. as well as At least one portion of the substance that specifically binds to the target tumor antigen expressed in T-cell tumor cells includes a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:119 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:120, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:121 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:122 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:123 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:124.
[0259] In a specific manner, among the bispecific antigen-binding molecules constituting the therapeutic agent of the present invention, At least one portion of TRBC1 or TRBC2 specifically binds to TRBC1 or TRBC2 expressed in normal T cells. (a) is at least one portion that specifically binds to TRBC1 expressed in normal T cells, comprising a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or Contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:149, or (b) At least one portion specifically binding to TRBC2 expressed in normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:7, and At least one portion that specifically binds to a target tumor antigen expressed in T-cell tumor cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:141 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:142.
[0260] In a further specific manner, to improve the binding affinity and / or other biological properties of the tumor antigen-binding moiety, amino acid sequence variants of bispecific antigen-binding molecules containing the tumor antigen-binding moiety are created. These amino acid sequence variants can be created, for example, by introducing suitable mutations (deletions, insertions, and substitutions) into the nucleotide sequence encoding the antibody or through peptide synthesis. Mutations can be introduced into the complementarity-determining region (CDR) or frame (FR) of the antibody, depending on the property to be improved. For the amino acid sequence variants, screening is performed for preservation or improvement of binding affinity, preservation or improvement of antigen specificity, reduction of immunogenicity, etc.
[0261] The table below shows the CDR sequences of each tumor antigen-binding region.
[0262] [Table 2]
[0263] (Configuration) In a particular embodiment, in the bispecific antigen-binding molecule constituting the therapeutic agent of the present invention, at least one portion specifically binding to an antigen having a subtype expressed in normal T cells is an scFv, and at least one portion specifically binding to a target tumor antigen expressed in T cell tumor cells is a Fab fragment, wherein the scFv is linked to the C-terminus of the heavy chain of the Fab fragment via a peptide linker. In a further particular embodiment, in the bispecific antigen-binding molecule, at least one portion specifically binding to an antigen having a subtype expressed in normal T cells is an scFv, and at least one portion specifically binding to a target tumor antigen expressed in T cell tumor cells is an scFv, wherein the two scFVs are linked via a peptide linker.
[0264] A "peptide linker" is a peptide containing approximately 2 to 20 amino acids, such as (G4S)n, (SG4)n, or G4(SG4)n, where "n" is usually an integer from 1 to 10. Typically, the peptide linker is selected from GGGGS (SEQ ID NO:51), GGGGSGGGGS (SEQ ID NO:52), GGGGSGGGGSGGGGS (SEQ ID NO:64), SGGGGSGGGG (SEQ ID NO:53), and GGGGSGGGGSGGG (SEQ ID NO:54), and the sequences GSPGSSSSGS (SEQ ID NO:55), (G4S)4, GSGSGSGS (SEQ ID NO:56), GSGSGNGS (SEQ ID NO:57), GGSGSGSG (SEQ ID NO:58), GGSGSG (SEQ ID NO:59), GGSG (SEQ ID NO:60), GGSGNGSG (SEQ ID NO:61), GGNGSGSG (SEQ ID NO:62), and GGNGSG (SEQ ID NO:63).
[0265] In a specific embodiment, the bispecific antigen-binding molecule constituting the therapeutic agent of the present invention further comprises an Fc domain. In a further specific embodiment, the Fc domain is the Fc domain of IgG1, IgG2, IgG3, or IgG4, preferably the IgG1 Fc domain. In a further specific embodiment, the polypeptide of the IgG1 Fc domain may have one or more amino acid mutations, particularly preferably amino acid mutations that alter the binding affinity to the Fc receptor, and more preferably amino acid mutations that reduce the binding affinity to the Fc receptor.
[0266] In a specific manner, the Fc domain is a human IgG1 isotype that can have a leucine mutation at positions 234 and 235, resulting in L234AL235A (LALA mutation) or a corresponding mutation, for alanine. These mutations can occur at the same positions in other isotypes and subtypes. The LALA mutation renders binding to complement components (C1q) and Fcγ receptors (FcgR) ineffective, thus preventing in vitro FcgR-mediated co-activation of natural immune effector cells, including natural killer (NK) cells, monocytes / macrophages, and neutrophils, without altering their functional binding to FcRn (fetal Fc receptor) (ClinCancer Res (2016) 22 (13): 3286-3297.). Consequently, bispecific antigen-binding molecules with an Fc domain carrying the LALA mutation lack complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) activity, and the only immune effector cell involved can be a T cell.
[0267] In a specific manner, the configuration of the bispecific antigen-binding molecule can be any of the structures / configurations described in ULRICH H. WEIDLE et al., “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer”, Cancer Genomics & Proteomics, January 2013, 10(1) 1-18. Examples include, for instance, cross Mab, IgG-dssFv2, DVD, IgG-dsFv, IgG-scFab, scFab-dssFv, Fv2-Fc, Fab-scFv2, Fab-scFv, Fab-scFv-Fc, BiTE (scFv-scFv), diabody, DART, etc., but are not limited to these.
[0268] In a specific manner, the bispecific antigen-binding molecule is monovalent relative to both the target antigen expressed on the side of normal T cells and the target tumor antigen expressed on T cell tumor cells.
[0269] In a specific manner, the bispecific antigen-binding molecule is bivalent to both the target antigen expressed on the side of normal T cells and the target tumor antigen expressed on T cell tumor cells.
[0270] In a specific manner, the bispecific antigen-binding molecule is trivalent relative to both the target antigen on the side of normal T cells and the target tumor antigen expressed in T cell tumor cells.
[0271] In a specific manner, the bispecific antigen-binding molecule is monovalent relative to the target antigen on the normal T cell side and divalent relative to the target tumor antigen expressed on the T cell tumor cell side.
[0272] In a specific manner, the bispecific antigen-binding molecule is divalent relative to the target antigen on the normal T cell side and monovalent relative to the target tumor antigen expressed on the T cell tumor cell side.
[0273] In a specific manner, the bispecific antigen-binding molecule has a structure with two scFv fragments that specifically bind to target antigens on the side of normal T cells (e.g., TRBC1 or TRBC2) and a Fab fragment that specifically binds to target tumor antigens expressed in T cell tumor cells, connected by a peptide linker (i.e., bivalent + bivalent), and further, a structure having an Fc domain (Fab-scFv-Fc).
[0274] In certain ways, the therapeutic agents of the present invention can be administered in combination with chemotherapeutic agents, radiation and / or other agents used in cancer immunotherapy.
[0275] The dosage and interval of the therapeutic agent of the present invention can be individually adjusted to provide sufficient plasma levels of the bispecific antigen-binding molecules of the present invention required to maintain the therapeutic effect. The dosage varies from about 0.1 to 50 mg / kg / day, depending on the target therapeutic effect, method of administration, treatment duration, age, weight, etc. A therapeutically effective plasma level can be achieved by administering multiple doses daily. The plasma level can be determined, for example, by HPLC.
[0276] In combination therapy, the therapeutic agent of the present invention and one or more drugs or therapies can be administered simultaneously or sequentially. When administered simultaneously or sequentially, all drugs or therapies can be administered via the same route, or they can be administered via different routes.
[0277] In this instruction manual, "simultaneous administration" means administering two or more drugs or therapies at intervals of several minutes to less than a few seconds. For example, administering two drugs or therapies at intervals of approximately 15 minutes to less than 1 minute. "Sequential administration" in this instruction manual means administering drugs at intervals of several minutes, hours, days, or weeks. For example, administering two drugs or therapies after intervals of more than 15 minutes, more than 30 minutes, more than 60 minutes, or 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days, or 2 weeks, 3 weeks, or 4 weeks.
[0278] The therapeutic agent of the present invention may be a pharmaceutical composition. The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. Formulations of pharmaceutical compositions having pharmaceutically acceptable carriers are well known in the art (e.g., Remington: The Science and Practice of Pharmacy (23rd edition (2020)). Pharmaceutically acceptable carriers include buffers such as phosphates, citrates, and other organic acids; antioxidants such as ascorbic acid; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates comprising glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG), but are not limited thereto.
[0279] The manufacture of the pharmaceutical compositions of the present invention is preferably carried out under conditions (Good Manufacturing Practice, GMP) that are suitable for the manufacturing and quality management rules of pharmaceuticals and quasi-pharmaceuticals.
[0280] In one embodiment, the pharmaceutical composition is a liquid such as a solution, suspension, emulsion, microemulsion, or gel. The pharmaceutical composition may be an aqueous formulation containing at least 50% (w / w) water. In another embodiment, the dosage form of the pharmaceutical composition is suitable for injection. Injection may be subcutaneous, intramuscular, intraperitoneal, intravitreal, or intravenous.
[0281] In one approach, the pharmaceutical composition may be in solid dosage form. Solid dosage form may be, for example, lyophilized or spray-dried, and may be administered by adding solvents and / or diluents prior to administration.
[0282] The pharmaceutical composition may be provided in packaging such as syringes, vials, or infusion bags. Syringes may contain the pharmaceutical composition in lyophilized form (which needs to be dissolved in, for example, water for injection) or aqueous form before administration. Alternatively, as a solid dosage form, it may be a powder, granules, tablet, or capsule.
[0283] In a particular manner, the therapeutic agent of the present invention can be used to treat a T-cell tumor in a subject with T-cell dysfunction, the method comprising: determining a subtype expressed in the subject's T-cell tumor cells, and administering the therapeutic agent to the subject; the therapeutic agent comprises a bispecific antigen-binding molecule comprising at least one portion specifically binding to a normal T-cell side-target antigen, the subtype of which differs from the subtype determined to be expressed in the subject's T-cell tumor cells. The subtype of the antigen expressed in the subject's T-cell tumor cells can be determined using a fluorescently labeled antibody that specifically binds to the subtype, determined by flow cytometry analysis. When the antigen is TRBC and the subtype is TRBC1, a JOVI-1 clone antibody can be used; when the subtype is TRBC2, various antibodies described in WO2020 / 089644 can be used.
[0284] A second embodiment of the present invention is a method for treating T-cell tumors in a subject with T-cell dysfunction, the method comprising administering a bispecific antigen-binding molecule to the subject having a T-cell tumor.
[0285] In a particular manner, the treatment method further includes identifying a subtype of a normal T-cell side-target antigen expressed in the subject's T-cell tumor cells, the bispecific antigen-binding molecule comprising at least one portion specifically binding to the normal T-cell side-target antigen, the subtype of which differs from the subtype identified as being expressed in the subject's T-cell tumor cells.
[0286] In certain approaches, the treatment may further include determining that the subject is in a state of T-cell dysfunction. T-cell dysfunction can be detected, for example, by comparing the expression levels of immunosuppressive checkpoint molecules (e.g., PD-1, TIM-3, CTLA-4, LAG-3, or TIGIT) in the subject's T cells to their expression levels in normal T cells. Increased expression levels of immunosuppressive checkpoint molecules in T cells compared to their expression levels in normal T cells suggest T-cell dysfunction. The expression levels of immunosuppressive checkpoint molecules in normal T cells can be, for example, the expression levels of immunosuppressive checkpoint molecules in normal individuals, the average expression levels of immunosuppressive checkpoint molecules in the T cells of multiple normal individuals, or the expression levels of immunosuppressive checkpoint molecules in samples collected from the patient before they entered a state of T-cell dysfunction. The expression of immune checkpoint molecules can be determined, for example, using fluorescently labeled antibodies and analyzed by flow cytometry.
[0287] If the subject is in a state of T cell dysfunction, this can also be detected by comparing the gene expression profile of T cells from the subject with that from T cells from healthy individuals. Gene expression profiling can be performed using bulk RNA-seq or scRNA-seq analysis, as detailed above.
[0288] The third embodiment of the present invention is the use of a bispecific antigen-binding molecule in the manufacture of a medicament for treating T-cell tumors in subjects with T-cell dysfunction.
[0289] The bispecific antigen-binding molecules in the second and third embodiments of the present invention are the same as the bispecific antigen-binding molecules constituting the therapeutic agent of the first embodiment described above in this specification.
[0290] The term “object” as used in this specification means mammals, such as mice, rats, primates, and especially humans.
[0291] <Bispecific antigen-binding molecules> The fourth embodiment of the present invention relates to a bispecific antigen-binding molecule for a treatment method for T-cell tumors in subjects with T-cell dysfunction.
[0292] The bispecific antigen-binding molecule of the present invention for a treatment method for T-cell tumors in subjects with T-cell dysfunction comprises: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; At least one portion of an antigen that specifically binds to a subtype of a normal T cell lateral target antigen is at least one portion (TRBC1 binding portion or TRBC2 binding portion) that specifically binds to TRBC1 or TRBC2 (T cell receptor β constant region 1 or 2) of a normal T cell.
[0293] The amino acid sequences of the TRBC1-binding or TRBC2-binding and target tumor antigen-binding portions of the bispecific antigen-binding molecule of the present invention are the same as those described above concerning the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment. Furthermore, the configurations that the bispecific antigen-binding molecule of the present invention may employ are the same as those described above in this specification concerning the bispecific antigen-binding molecule constituting the therapeutic agent of the first embodiment.
[0294] Furthermore, according to the present invention, a nucleic acid molecule encoding the heavy and light chains of the bispecific antigen-binding molecule of the fourth embodiment is provided. The nucleic acid molecule of the present invention may be RNA, DNA, or cDNA.
[0295] The nucleic acid molecules of the present invention may be in the form of a vector, or may exist within a vector, and / or may be part of a vector such as a plasmid, granule, or YAC. The vector may be, in particular, an expression vector, or a vector that provides expression of the bispecific antigen-binding molecule of the present invention in a host cell, host organism, and / or expression system. The expression vector typically comprises at least one nucleic acid of the present invention operatively linked to one or more suitable expression regulatory elements (e.g., promoters, enhancers, terminators, etc.). The selection of the elements and their sequences for expression in a particular host is a common understanding among those skilled in the art. Specific examples of regulatory elements and other elements useful or indispensable in the expression of the heavy and light chains of the bispecific antigen-binding molecule of the present invention include promoters, enhancers, terminators, integrative elements, selection markers, leader sequences, reporter genes, etc.
[0296] The nucleic acid molecules of the present invention can be prepared or obtained by known methods (e.g., by automated DNA synthesis and / or recombinant DNA technology) based on information related to the amino acid sequences of the heavy and light chains of the bispecific antigen-binding molecules of the present invention disclosed in this specification, and / or can be isolated from suitable natural resources.
[0297] Furthermore, according to the present invention, one or more host cells expressing or capable of expressing the heavy and light chains of the bispecific antigen-binding molecule of the fourth embodiment are provided. The host cells of the present invention may contain nucleic acids or vectors. Preferred host cells of the present invention are bacterial cells, fungal / yeast cells, or mammalian cells.
[0298] Appropriate bacterial cells include cells of Gram-negative strains (e.g., Escherichia coli, Proteus, and Pseudomonas) and Gram-positive strains (e.g., Bacillus, Streptomyces, Staphylococcus, and Lactococcus).
[0299] Suitable fungal and yeast cells include cells from species of the genera *Trichoderma*, *Neurospora*, and *Aspergillus*; or cells from species of the genera *Saccharomyces*, such as *Schizosaccharomyces* pombe, *Pichia*, such as *Pichia pastoris* and *Pichia amethanolica*, and *Hansenula*. Suitable mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, etc.
[0300] However, amphibian cells, insect cells, plant cells, and any other cells in this field used to express heterologous proteins can also be used in this invention.
[0301] The heavy and light chains of the bispecific antigen-binding molecule of the present invention can be generated intracellularly as described above, then isolated from host cells, and optionally further purified. Alternatively, they can be generated extracellularly (e.g., in a culture medium for culturing host cells), then isolated from the culture medium, and optionally further purified.
[0302] Methods and reagents for the recombinant production of peptides, such as specific suitable expression vectors, transformation or transfection methods, selection markers, methods for inducing protein expression, and culture conditions, are well known in the art. Similarly, protein isolation and purification techniques suitable for the methods of producing the bispecific antigen-binding molecules of the present invention are well known to those skilled in the art.
[0303] However, the bispecific antigen-binding molecule of the present invention can also be obtained by other protein production methods known in the art, including chemical synthesis, which includes solid-phase or liquid-phase synthesis.
[0304] (Cytotoxic activity) The bispecific antigen-binding molecule of the present invention, having a TRBC1-binding or TRBC2-binding portion, can mobilize TRBC1-positive or TRBC2-positive T cells to induce cytotoxicity and / or cell death in tumor cells. The cytotoxic activity of the bispecific antigen-binding molecule can be determined in vitro by culturing target tumor cells with the bispecific antigen-binding molecule in the presence of effector cells and measuring the survival rate of the target tumor cells. Activated T cells (e.g., T-LAK) can be used as effector cells. The mixing ratio of effector cells to target tumor cells can be from 10:1 to 1:10. In one embodiment, the bispecific antigen-binding molecule of the present invention can induce cytotoxicity of tumor cells in vitro at an EC50 of less than about 500 pM; preferably, it can induce cytotoxicity at EC50s of less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, or less than about 50 pM.
[0305] Anti-TRBC1 antibodies against the TRBC1 binding portion of the bispecific antigen-binding molecule used in this invention can increase the percentage of TRBC1-positive cells in human peripheral blood mononuclear cells (PBMCs). Specifically, as shown in Reference Example 1 described later, the addition of 10 nM of anti-TRBC1 antibody to human PBMCs, when cultured in the presence of IL-2, increased the proportion of TRBC1-positive cells from 30% on Day 0 to over 80% on Day 15. This suggests that TRBC1-positive cells selectively proliferate by adding anti-TRBC1 antibodies. It is believed that TRBC1-positive cells also selectively proliferate by adding bispecific antibodies with the same antigen-binding portion as anti-TRBC1 antibodies.
[0306] Anti-TRBC1 antibodies against the TRBC1 binding site of the bispecific antigen-binding molecule used in this invention can increase cytotoxic T cells in the presence of IL-2. Specifically, as shown in Reference Example 1 described later, on day 15, in the presence of anti-TRBC1 antibody and IL-2, the proportion of effector memory T cells increased significantly from about 20% to about 70%. Based on this result, it is believed that stimulation with anti-TRBC1 antibody can increase the number of T cells causing cytotoxic effects. It is also believed that stimulation with a bispecific antibody having the same antigen-binding site as anti-TRBC1 antibody can similarly increase the number of T cells causing cytotoxic effects.
[0307] Anti-TRBC1 antibodies against the TRBC1 binding site of the bispecific antigen-binding molecule used in this invention can activate T cells. Specifically, as shown in Reference Example 1 described later, it is implied that stimulation with anti-TRBC1 antibodies increases the percentage of CD69, granzyme B, and perforin-positive cells, and TRBC1-positive cells are activated by the anti-TRBC1 antibodies. T cell activation can also be expected with bispecific antibodies having the same antigen-binding site as the anti-TRBC1 antibody used in this example.
[0308] As shown in Reference Example 1 described later, stimulation with an anti-TRBC1 antibody, which utilizes the TRBC1 binding site of the bispecific antigen-binding molecule of the present invention, did not cause a significant change in the ratio of PD-1 positive cells. This suggests that even when T cells are activated using an anti-TRBC1 antibody, T cells are not easily depleted. It is believed that bispecific antibodies having the same antigen-binding site as the anti-TRBC1 antibody used in this example are also less likely to cause T cell depletion.
[0309] As described in Reference Example 1 below, the anti-TRBC1 antibody, which is used for the TRBC1-binding portion of the bispecific antigen-binding molecule of the present invention, can induce T cell activation and release cytokines, but the release of IL-6, an inflammatory cytokine, is extremely low. This indicates a low risk of cytokine release syndrome from the anti-TRBC1 antibody. It also suggests that the risk of cytokine release syndrome is similarly low for bispecific antibodies having the same antigen-binding portion as the anti-TRBC1 antibody.
[0310] Anti-TRBC2 antibodies against the TRBC2-binding portion of the bispecific antigen-binding molecule used in this invention can increase the percentage of TRBC2-positive cells in PBMCs. Specifically, as shown in Reference Example 2 described later, for human PBMCs, after removing cells bound to TRBC1 antibodies (TRBC1-positive T cells) using beads, 10 nM of anti-TRBC2 antibody was added. When cultured in the presence of IL-2, the cell number was approximately 5 × 10⁶ to 7 × 10⁶ cells on Day 0, and increased to approximately 18 × 10⁶ to 42 × 10⁶ cells on Day 15. This suggests that TRBC2-positive cells selectively proliferate by adding anti-TRBC2 antibody. It is believed that even with the addition of a bispecific antibody having the same antigen-binding portion as the anti-TRBC2 antibody, TRBC2-positive cells also selectively proliferate.
[0311] Anti-TRBC2 antibodies against the TRBC2 binding site of the bispecific antigen-binding molecule used in this invention can increase cytotoxic T cells in the presence of IL-2. Specifically, as shown in Reference Example 2 described later, on day 15, in the presence of both anti-TRBC2 antibody and IL-2, the proportion of effector memory T cells increased dramatically from approximately 27% to approximately 81%. Based on this result, it is believed that stimulation with anti-TRBC2 antibody can increase the number of T cells causing cytotoxic effects. It is also believed that stimulation with bispecific antibodies having the same antigen-binding site as anti-TRBC2 antibody similarly increases the number of T cells causing cytotoxic effects.
[0312] TRBC2 antibodies, specifically those containing the TRBC2-binding portion of the bispecific antigen-binding molecule used in this invention, can activate T cells. Specifically, as illustrated in Reference Example 2 described later, stimulation with anti-TRBC2 antibodies suggests an increase in the percentage of CD69, granzyme B, and perforin-positive cells, indicating that TRBC2-positive cells are activated by the anti-TRBC2 antibodies. T cell activation can also be expected with bispecific antibodies that share the same antigen-binding portion as the anti-TRBC2 antibody.
[0313] Stimulation with an anti-TRBC2 antibody, which binds to the TRBC2-binding portion of the bispecific antigen-binding molecule used in this invention, as shown in the reference examples described later, does not cause a significant change in the percentage of PD-1 positive cells. This suggests that even when T cells are activated using an anti-TRBC2 antibody, T cells are not easily depleted. Similarly, it is believed that T cells are not easily depleted with bispecific antibodies that have the same antigen-binding portion as the anti-TRBC2 antibody.
[0314] As described in Reference Example 2 below, the anti-TRBC2 antibody, which is used for the TRBC2 binding portion of the bispecific antigen-binding molecule of the present invention, can induce T cell activation and release cytokines, but the release of IL-6, an inflammatory cytokine, is extremely low. This indicates a low risk of cytokine release syndrome from the anti-TRBC1 antibody. It also suggests that the risk of cytokine release syndrome is similarly low for bispecific antibodies having the same antigen-binding portion as the anti-TRBC1 antibody.
[0315] The bispecific antigen-binding molecule of the present invention, having a TRBC1-binding or TRBC2-binding portion, can be used in methods for the following applications: (i) Used to induce cytotoxicity in tumor cells, (ii) Used to increase the percentage of TRBC1-positive cells or increase the percentage of TRBC2-positive cells. (iii) Used to increase cytotoxic T cells, (iv) Used to activate T cells, (v) Used to stimulate or enhance cellular responses without exhausting T cells. (vi) Used to stimulate or enhance cellular responses without increasing the risk of cytokine release syndrome. (vii) Used to treat T-cell tumors in subjects with T-cell dysfunction. (viii) Used to delay the progression of T-cell tumors, or (ix) Used to prolong the survival of subjects with T-cell tumors.
[0316] The bispecific antigen-binding molecule of the present invention can have antitumor activity. This antitumor activity can be measured in vivo, for example. For instance, immunodeficient NSG mice (Jackson Laboratory, Japan) were intravenously transplanted with 1 x 10⁷ human PBMC cells per mouse. Seven to ten days later, a luciferase-stable T-cell tumor line was intravenously transplanted at 1 x 10⁷ cells per mouse. The bispecific antigen-binding molecule of the present invention was then administered at a dose of 0.5 mg / kg twice weekly. Two to three weeks after the start of administration, luciferase was administered intraperitoneally to the mice at 150 mg / kg. The in vivo luciferase activity was quantified using an IVIS imaging system (Revvity Corporation), thereby measuring the amount of T-cell tumors. The antitumor activity can be evaluated by comparing the amount of T-cell tumors in the control group and the group treated with the bispecific antigen-binding molecule of the present invention. Example
[0317] The invention is illustrated in more detail by way of the following examples, but the invention is not limited to these examples.
[0318] <Example 1> Preparation of Bispecific Antibody 1.1 Bispecific antibodies In this embodiment, a bispecific antibody that binds to TRBC1 or TRBC2 and the target tumor antigen is prepared.
[0319] TRBC1 or TRBC2 combination part The TRBC1 binding portion was created based on the sequence information of the JOVI-1 clone of the anti-TRBC1 antibody described in US Patent No. 10730942 (US10730942 T-cell receptor knockdown based on protein SEQ ID No. 15, SEQ ID No. 16).
[0320] The TRBC2 binding portion is made based on the VH domain of hJOVI-1 in WO2020 / 089644 (SEQ ID NO:1 of WO2020 / 089644), which has three amino acids replacing T28K, Y32F and A100N (Table 1 (page 23) of WO2020 / 089644) and the VL domain of hJOVI-1 (SEQ ID NO:2 of WO2020 / 089644) (the VH and VL amino acid sequences described in SEQ ID NO:6 and 7 of this application).
[0321] The portion that binds to the target tumor antigen expressed in tumor cells is created based on the sequence information published in the literature as listed in the table below.
[0322] [Table 3]
[0323] The heavy and light chain sequences of the bispecific antibody prepared in this embodiment are shown below.
[0324] [Table 4]
[0325] Figure 2A The diagram shows the schematic diagrams of Fab-scFv, Fab-scFv-Fc, and Fab-Fc-scFv types.
[0326] CCR0010 is derived from the heavy chain of CCR0001 by introducing mutations in T255K, Y259F, and A327N, and its structure is Fab-scFv. Previously developed anti-TRBC-2 antibodies have a background obtained by introducing mutations into anti-TRBC-1 antibodies (JOVI-1) (e.g., WO2015 / 132598A1, WO2020 / 089644A1), and the amino acid sequences of their CDRs show high homology.
[0327] 1.2 Preparation and purification of recombinant antibodies The bispecific antibodies listed in Table 4 were constructed using expression vectors that expressed signal sequences on the heavy and light chains listed in Table 4, respectively. Details of the heavy and light chain composition of each bispecific antibody are as follows: Figure 3A The figures for -K are shown.
[0328] Specifically, bispecific antibody (heavy and light chain) expression vectors were constructed using DNA encoding bispecific antibodies and expression vectors (pcDNA3.4, Thermo Fisher Scientific). The combinations of the heavy and light chains of the bispecific antibodies are shown in Table 4. The expression vectors were mixed 1:1, and 0.8 μg of DNA per 1 mL of culture medium was introduced into CHO cells using ExpiFectamine CHO Reagent (Thermo Fisher Scientific). ExpiCHO Feed and ExpiFectamine CHO Enhancer were added on the second day and five days after transfection, and the cells were cultured at 32°C for 10–12 days. Cells were removed from the culture medium by centrifugation and filtration, and the culture supernatant was recovered. Antibody purification was performed using a combination of nickel-binding agarose affinity chromatography and gel filtration chromatography or a combination of protein A affinity chromatography and gel filtration chromatography.
[0329] <Example 2> Cell Preparation This embodiment describes the preparation of the cells used in the experiment.
[0330] Use the following reagents. RPMI 1640 medium (Nacalai Tesque, 30264-56) FBS (Fetal Bovine Serum) (Nichirei Biosciences, 175012): Protein inactivation was achieved by incubation in a 56°C water bath for 30 minutes. Penicillin-streptomycin mixed solution (Nacalai Tesque, 2625384) MEM non-essential amino acid solution (100X) (Gibco, 11140-050) Sodium pyruvate solution 100mM (Gibco, 11360-070) Anti-TRBC1 antibody (prepared and purified using the method described in Example 1. The heavy and light chain sequences of the anti-TRBC1 antibody used are SEQ ID NO: 144 and 145.) Imunace Note 35 (IL-2, Interleukin-2) (Shionogi & Kyowa Pharmaceutical Co., Ltd.): Dissolve in PBS to 250 IU / μL and store at -25°C. PBS (phosphate-buffered saline) (Gibco, 10010-023) Human PBMCs (peripheral blood mononuclear cells) (CTL, CTL-UP1).
[0331] The various cells are prepared as described below. T-LAK is a population of T cells expressing lymphokine-activated killer (LAK) function. T-LAK preparation was performed based on the experimental system optimized by OchoaAC et al. (Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2:identification and isolation of effector subsets. Cancer Res. 1989 Feb 15;49(4):963-8.). Specifically, human PBMCs were dissolved in a 37°C water bath and washed once with culture medium. After 2 days of culture in RPMI 1640 medium containing 10% FBS supplemented with 10 nM anti-TRBC1 antibody and 100 IU / mL IL-2, they were further cultured in RPMI 1640 medium containing IL-2 and 10% FBS (maximum 17 days) to induce T-LAK. Subculture was performed every 2–3 days, with 100 IU / mL IL-2 added each time the culture medium was changed. The cell counts were determined on the start of culture (Day 0) and day 15 (Day 15) using an automated cell counter (BIO RAD, TC20).
[0332] The MT-2 cells used in Example 3 were a human leukocyte cell line established through co-culture with human ATL (adult T-cell leukemia) cells. They were purchased from the JCRB cell bank (National Research and Development Corporation Therapeutic Agents Foundation, Health and Nutrition Institute) (cell number JCRB1210). MT-2 cells were CCR4 positive (Haematologica 2018 Volume 103(1):126-135). They were cultured in RPMI medium containing 10% FBS, non-essential amino acids, and sodium pyruvate in a 5% CO2 incubator at 37°C, and passaged 2-3 times per week.
[0333] The MOLT-4 cells used in Example 3 were purchased from the National Research and Development Corporation Therapeutic Agents Foundation, Health and Nutrition Institute. They were cultured in RPMI medium containing 10% FBS in a 5% CO2 incubator at 37°C, and passaged 2-3 times per week.
[0334] The CCRF-CEM9 cell line used in the following examples expresses CD1a and TRBC2. CCRF-CEM9 was obtained by monoclonalization of the CCRF-CEM cell line from TALL using a limiting dilution method. Specifically, the CCRF-CEM cell suspension was repeatedly diluted from 1 x 10⁵ cells / mL to a concentration of 2.5 cells / mL. 100 μL of the 2.5 cell / mL dilution was added to two 96-well plates and cultured at 37°C. Each well (clone) from which cells proliferated was scaled up for TRBC1 and CD1a expression analysis. The results confirmed the expression of both antigens in CCRF-CEM9. The cells were cultured in RPMI medium containing 10% FBS at 37°C with 5% CO₂, and passaged 2–3 times per week.
[0335] <Reference Example 1> Validation of the effector activity of anti-TRBC1 antibody and quantification of cytokine release. Use reagents Flow cytometry staining buffer (eBioscience, 00-4222-26) Clear Back (MBL, MT-001) The active dye eFluor780 (invitrogen, 65-0865-14) can be fixed. Transcription factor buffer kit (BD, 562574) TF Fix / Perm Buffer (4×) (51-9008100): Use after a 4-fold dilution with TF dilution buffer. TF dilution buffer (51-9008101) TF Perm / Wash Buffer (5×) (51-9008102): Use after a 5-fold dilution with distilled water. MILLIPLEX Human Cytokine / Chemokine / Growth Factor Component A (Millipore, HCYTA-60K).
[0336] The staining antibodies are shown in the table below.
[0337] [Table 5] ※BV421, BV711: Abbreviations for Brilliant Violet421 (registered trademark) and Brilliant Violet711 (registered trademark).
[0338] The anti-TRBC1 antibody, after being prepared and purified using the method described in Example 1, was labeled with pigments using a HiLyte Fluor 647 Labeling Kit-NH2 (Dojindo, LK15). The heavy and light chain sequences of the anti-TRBC1 antibody are SEQ ID NO: 144 and 145.
[0339] As an isotype control, human IgG (ChromPure Human IgG, full molecular weight, Jackson ImmunoResearch, 009-000-003) was also labeled with pigments.
[0340] method The experiment was conducted in accordance with WO2021 / 173896 A1.
[0341] Methods of cell surface staining Human PBMCs or T-LAK cells were centrifuged (300g × 5 min), the supernatant was removed, and clear back was added. After incubation at room temperature for 5 min, various antibodies were added to flow cytometry staining buffer, and the reaction was carried out at 4°C for 30 min. After the reaction, flow cytometry staining buffer was added, and the cells were centrifuged (500g × 2 min), and the supernatant was discarded. The cells were then washed twice. The signal was quantified by flow cytometry analysis using a BD LSRFortessa X-20 (BD Biosciences). The analysis software used was FlowJo_v10.6.1.
[0342] Methods of intracellular staining After centrifuging human PBMCs or T-LAK cells (300g × 5 min), the supernatant was removed, and Clear Back was added. After incubating at room temperature for 5 min, anti-CD3 and anti-TRBC1 antibodies were added to flow cytometry staining buffer, and the reaction was carried out at 4°C for 30 min. After the reaction, flow cytometry staining buffer was added, and the cells were centrifuged (500g × 2 min), and the supernatant was discarded, thus performing two cell washes. TF Fix / Perm buffer from the transcription factor buffer kit was added, and the cells were incubated on ice for 30 min for fixation and permeation. After centrifugation (700g × 2 min), TF Perm / Wash buffer was added, and the cells were centrifuged (700g × 2 min), and the supernatant was discarded, thus performing two cell washes. Anti-granzyme B antibody or anti-perforin antibody was added to TFPerm / Wash buffer, and the reaction was carried out on ice for 30 min. After the reaction, TF Perm / Wash buffer was added for centrifugation (700g × 2 min), and the supernatant was discarded. The cells were then washed twice, and the signal was quantified by flow cytometry using a BD LSRFortessa X-20 (BD Biosciences). FlowJo_v10.6.1 was used for analysis.
[0343] Quantitative methods for cytokine release After culturing T-LAK cells with anti-TRBC1 antibody for 24 hours, the release of various cytokines was quantified using the Millipex Human Cytokine / Chemokine / Growth Factor Component A. T-LAK cells were washed once with RPMI 1640 medium (culture medium) containing 10% FBS, and the appropriate cell count was performed before adding them to 384-well plates. Anti-TRBC1 antibody was prepared to final concentrations of 0, 0.1, 1.0, and 10 nM using culture medium and added to the wells containing T-LAK cells. The plates were incubated at 37°C for 24 hours with 5% CO2. After centrifugation (300 g, 5 min) of the 384-well plates, the supernatant was collected, and IFN-γ, IL-2, IL-6, IL-10, and TNF-α were quantified using the Millipex Human Cytokine / Chemokine / Growth Factor Component A. The quantification values were automatically calculated using a Luminex 200xPONET 3.1 system.
[0344] result TRBC1 positive cell rate Figure 4AFigures B and B show an increase in the percentage of TRBC1-positive cells after the addition of anti-TRBC1 antibody. Compared to human PBMCs, the addition of 10 nM anti-TRBC1 antibody, when cultured in the presence of IL-2, increased the proportion of TRBC1-positive cells from 30% on Day 0 to strongly 80% on Day 15. This suggests that TRBC1-positive cells selectively proliferate upon the addition of anti-TRBC1 antibody. It is believed that even the addition of a bispecific antibody with the same antigen-binding moiety as the anti-TRBC1 antibody used in this experiment resulted in similar selective proliferation of TRBC1-positive cells.
[0345] Increase in cytotoxic T cells like Figure 5A As shown in Figure B, T-LAK cells from Day 0 and Day 15 were stained with CD27 and CD45RA, and the cell ratios of the effector memory, central memory, naive, and EMRA fractions were calculated. The results showed that by Day 15, the proportion of effector memory cells increased dramatically from approximately 20% to approximately 70%, while the proportions of the other fractions decreased. Based on these results, it is concluded that stimulation with anti-TRBC1 antibody can increase the number of T cells induced by cytotoxicity. It is also believed that stimulation with a bispecific antibody having the same antigen-binding moiety as the anti-TRBC1 antibody used in this experiment also resulted in an increase in the number of T cells induced by cytotoxicity.
[0346] Evaluation of T cell activation markers CD69 is a cell surface glycoprotein expressed very early after activation of T cells or B cells, but not expressed in resting lymphocytes. Cytotoxic T cells possess intracellular granules containing cytotoxic proteins (granzyme B, perforin). Granzyme B is a serine protease that, once delivered to target cells, cleaves various intracellular matrix components, including caspase, inducing apoptosis in the target cells. Perforin disrupts the cell membrane of target cells, promoting the delivery of granzyme B into the target cells.
[0347] Figure 6 shows the results of analyzing the positive cell ratios of CD25, CD69, granzyme B, and perforin using T-LAK on Day 0 and Day 15.
[0348] In this experiment, the percentage of CD25-positive cells decreased, while the percentages of CD69, granzyme B, and perforin-positive cells increased, suggesting that TRBC1-positive cells were activated by the anti-TRBC1 antibody. Similar effects are expected for bispecific antibodies with the same antigen-binding moiety as the anti-TRBC1 antibody used in this experiment. In this experiment, it is speculated that the addition of IL-2 during culture induced CD25 internalization and downregulation, leading to decreased CD25 expression.
[0349] Changes in the ratio of PD-1 positive cells Figure 7 shows the results of analyzing the percentage of PD-1-positive cells, one of the immunosuppressive checkpoint molecules for T cells, using T-LAK on Day 0 and Day 15. In effector memory (EM) cells of functional cytotoxic T cells, expression of immunosuppressive checkpoint molecules such as PD-1 and TIGIT was almost entirely absent. In contrast, high expression of these immunosuppressive checkpoint molecules was observed in non-functional, exhausted T cells. According to the results in Figure 7, the percentage of PD-1-positive cells did not change significantly. This suggests that even when T cells are activated with anti-TRBC1 antibodies, they are not easily exhausted. Similarly, bispecific antibodies with the same antigen-binding moiety as the anti-TRBC1 antibody used in this experiment are also considered less likely to cause T cell exhaustion.
[0350] Quantitative analysis of cytokine release Figure 8 This paper presents quantitative results of the release of IFN-γ, IL-2, IL-6, IL-10, and TNFα after 24 hours of stimulation with 0.1, 1.0, or 10 nM anti-TRBC1 antibody using Day 15 T-LAK cells. The results confirmed a concentration-dependent increase in the release of each cytokine, suggesting that T cells are induced to activate and release cytokines via anti-TRBC1 antibody. In this experimental system, the release of the inflammatory cytokine IL-6 was minimal. These data suggest a low risk of cytokine release syndrome caused by anti-TRBC1 antibody. This also suggests a similarly low risk for bispecific antibodies with the same antigen-binding moiety as the anti-TRBC1 antibody used in this example.
[0351] <Reference Example 2> Evaluation of anti-TRBC2 antibody agonist activity The anti-TRBC2 antibody was prepared and purified using the method described in Example 1. The heavy and light chain sequences of the anti-TRBC2 antibody are SEQ ID NO: 146 and 147. The reagents and staining antibodies used in this reference example are the same as those described in Reference Example 1.
[0352] result TRBC2 positive cell count Human PBMCs were dissolved and washed in a 37°C water bath. The washed human PBMCs were reacted with JOVI-1 mIgG (SantaCruz) at 4°C for 30 minutes. After washing, the antibody-reacted PBMCs were resuspended in culture medium and reacted with Dynabeads M-280 anti-mouse IgG (Invitrogen) at 4°C for 30 minutes. Using DynaMag (Invitrogen), bead-unwanted cell conjugates were aggregated on the tube wall, and the supernatant containing TRBC2-positive T cells was collected. The collected cells were cultured for 2 days in RPMI 1640 medium containing 10% FBS supplemented with 10 nM anti-TRBC2 antibody and 100 IU / mL IL-2, followed by further culture in RPMI 1640 medium containing IL-2 and 10% FBS (maximum 17 days) to induce T-LAK. Subcultures were performed every 2–3 days, with 100 IU / mL IL-2 added fresh each time the culture medium was changed.
[0353] The cell counts were determined on the start of culture (Day 0) and day 15 (Day 15) using an automated cell counter (BIO RAD, TC20).
[0354] [Table 6]
[0355] On Day 0, the number of cells was approximately 5 × 10⁶ to 7 × 10⁶, which increased to approximately 18 × 10⁶ to 42 × 10⁶ cells on Day 15. Figure 9 This suggests that the addition of anti-TRBC2 antibody selectively proliferates TRBC2-positive cells. It is believed that even the addition of a bispecific antibody with the same antigen-binding moiety as the anti-TRBC2 antibody used in this experiment resulted in the selective proliferation of TRBC2-positive cells.
[0356] Increase in cytotoxic T cells like Figure 10 As shown, T-LAK cells were sensitized with anti-TRBC2 antibody on Day 0 and Day 15, stained with CD27 and CD45RA, and the cell ratios of effector memory (EM), central memory (CM), naive, and EMRA fractions were calculated. The results showed that by Day 15, the proportion of effector memory increased significantly from approximately 27% to approximately 81%, while the proportions of the other fractions decreased. Based on these results, it is concluded that stimulation with anti-TRBC2 antibody can increase the number of T cells induced by cytotoxicity. It is also believed that stimulation with a bispecific antibody having the same antigen-binding moiety as the anti-TRBC2 antibody used in this experiment also increases the number of T cells induced by cytotoxicity. It should be noted that CD3-positive and TRBC1-negative cell populations were defined as TRBC2-positive cells.
[0357] Evaluation of T cell activation markers Figure 11 shows the results of sensitizing T-LAK cells with anti-TRBC2 antibodies on Day 0 and Day 15, and analyzing the positive cell ratios for CD25, CD69, granzyme B, and perforin. In this experiment, the percentage of CD25-positive cells decreased, while the percentages of CD69, granzyme B, and perforin-positive cells increased, suggesting that TRBC2-positive cells were activated by the anti-TRBC2 antibody. Similar effects can be expected with bispecific antibodies that have the same antigen-binding moiety as the anti-TRBC2 antibody used in this experiment. In this experiment, it is speculated that the addition of IL-2 during culture caused internalization and downregulation of CD25, resulting in decreased CD25 expression. It should be noted that the cell population that was CD3-positive and TRBC1-negative was defined as TRBC2-positive cells.
[0358] Changes in the ratio of PD-1 positive cells Figure 12 This analysis presents the results of sensitizing T-LAK cells with anti-TRBC2 antibody on Day 0 and Day 15, and analyzing the percentage of PD-1-positive cells, one of the immunosuppressive checkpoint molecules for T cells. In effector memory (EM) cells of functional cytotoxic T cells, the expression of immunosuppressive checkpoint molecules such as PD-1 and TIGIT was almost entirely absent; in contrast, high expression of these immunosuppressive checkpoint molecules was observed in non-functional, exhausted T cells. Based on... Figure 12 The results showed no significant change in the percentage of PD-1 positive cells. This suggests that even when T cells are activated with anti-TRBC2 antibody in the same manner as with anti-TRBC1 antibody, T cells are not easily exhausted. Similarly, for bispecific antibodies with the same antigen-binding moiety as the anti-TRBC2 antibody used in this experiment, T cells are also considered to be less prone to exhaustion.
[0359] Quantitative analysis of cytokine release Figure 13 This study presents quantitative results of the release of IFN-γ, IL-2, IL-6, IL-10, and TNFα from Day 15 T-LAK cells after 24 hours of stimulation with 0.1, 1.0, or 10 nM anti-TRBC2 antibody. The results confirmed a concentration-dependent increase in the release of each cytokine, suggesting that T cells are induced to activate and release cytokines via anti-TRBC2 antibody. In this experimental system, the release of the inflammatory cytokine IL-6 was minimal. These data suggest a low risk of cytokine release syndrome from anti-TRBC1 antibody. This also suggests a similarly low risk for bispecific antibodies with the same antigen-binding moiety as the anti-TRBC2 antibody used in this experiment.
[0360] <Example 3> Cytotoxic activity of anti-CCR4 / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the bispecific antibody prepared in Example 1, target cells were cultured with T-LAK (effective cells) in the presence of the specific antibody. The cell viability of the target cells was measured using fluorescent dye (calcein activity) as an indicator, and the effector cell-dependent cytotoxic activity was evaluated. The experiment was conducted in accordance with Neri S et al. (Clin Diagn Lab Immunol. 2001 Nov;8(6):1131-5).
[0361] Use the following reagents. HBSS (Hank's Balanced Salt Solution) is phenol red-free (Gibco, 14025092). RPMI 1640 Medium, Phenol Red Free (Gibco, 11835-030) Water-soluble probenecid (Invitrogen, P36400) Calcein-AM (invitrogen, C1430) 10X lysis buffer (Promega, G1821).
[0362] 3.1 Cytotoxic activity of bispecific antibodies against MT-2 cells method Bispecific antibodies were prepared to a final concentration of 100 nM–100 fM using RPMI phenol-free medium (assay medium) containing 5 mM probenecid and 0.5% FBS, and added to 96-well round-bottom plates. As a control, wells containing only the assay medium were set up.
[0363] To assess the cytotoxic activity of bispecific antibodies with a CCR4 binding moiety, the required amount of MT-2 cells (target cells) were recovered from the culture medium and washed twice with HBSS. Target cells were labeled with calcein by incubating with 10 μM calcein-AM supplemented with 5 mM probenecid at 37°C for 30 minutes. After incubation, the cells were washed three times with HBSS, and after the final wash, they were resuspended in assay medium. The number of labeled target cells was counted and added to 96-well round-bottom plates prepared with bispecific antibodies. The required amount of effector cells were recovered from the culture medium, washed once with assay medium, counted, and added to 96-well round-bottom plates prepared with bispecific antibodies. The ratio of effector cells to labeled target cells was 10:1. The plates containing bispecific antibodies, labeled target cells, and effector cells were incubated at 37°C with 5% CO2 for 2 hours. After centrifuging the 96-well round-bottom culture plates (300g, 5 minutes), the supernatant was recovered, and the fluorescence of calcein dissolved from the labeled target cells in the supernatant was measured using a microplate reader (Bio Tek, SYNERGY H1). The percentage of cytotoxicity of the target cells was calculated based on the fluorescence value of calcein to evaluate the bispecific antibody-dependent cytotoxic activity.
[0364] The percentage of cytotoxicity is calculated as follows. The minimum dissolution fluorescence value (solution rate = 0%) for labeled target cells was obtained from wells incubated with labeled target cells and effector cells without any bispecific antibodies. The maximum dissolution fluorescence value (solution rate = 100%) was obtained by adding 10× lysis buffer to wells under the same conditions as the minimum dissolution fluorescence value.
[0365] Calculate the percentage of cytotoxicity using the following formula: Cytotoxicity percentage = [(dissolution fluorescence value of target cells in the presence of bispecific antibody) - (minimum dissolution fluorescence value)] / [(maximum dissolution fluorescence value) - (minimum dissolution fluorescence value)].
[0366] The S-shaped dose-response curve was calculated using Prism software (GraphPad Software Inc.), which yielded the EC50 value (50% effective concentration) and the Emax value (maximum activity value).
[0367] result Figure 14A The table below shows the results of adding T-LAK to MT-2 cells, an ATL-derived cell line expressing CCR4, and measuring the cytotoxic activities of the bispecific antibodies CCR0001 and CCR0004.
[0368] The EC50 and Emax values (N=3) are shown in the table below.
[0369] [Table 7]
[0370] The bispecific antibodies CCR0001 and CCR0004, which are anti-CCR4 and anti-TRBC1, are considered to have very strong cytotoxic activity against CCR4-expressing cells.
[0371] 3.2 Cytotoxic activity of negative control antibody against MT-2 cells Anti-CCR4 antibody, anti-TRBC1 antibody, and combinations thereof (anti-CCR4 antibody + anti-TRBC1 antibody) were used as negative control antibodies, and cytotoxic activity was determined by the above method.
[0372] The anti-CCR4 antibody used in this example is mogliflozin. The anti-TRBC2 antibody was prepared and purified using the method described in Example 1. The heavy and light chain sequences of the anti-TRBC1 antibody are SEQ ID NO: 144 and 145.
[0373] Figure 14B The table below shows the results of adding T-LAK to MT-2 cells, an ATL-derived cell line expressing CCR4, and measuring the cytotoxic activity of the negative control antibody.
[0374] The EC50 and Emax values (N=3) are shown in the table below.
[0375] [Table 8] *For the anti-CCR4 antibody, calculation was not possible for one of the three tests; therefore, the average of the two tests is recorded. NC: Not calculated.
[0376] T-LAK was added to MT-2 cells, an ATL-derived cell line expressing CCR4, followed by the addition of anti-CCR4 antibody alone, anti-TRBC1 antibody alone, or both anti-CCR4 and anti-TRBC1 antibodies, and cytotoxic activity was measured. The results showed significantly lower EC50 and Emax values compared to when the bispecific anti-CCR4 / anti-TRBC1 antibodies CCR0001 and CCR0004 were added. The anti-CCR4 antibody did not exhibit sufficient cytotoxic activity in this experimental system. The anti-TRBC1 antibody also did not show sufficient cytotoxic activity.
[0377] 3.3 Cytotoxic activity of bispecific antibodies against negative control cells MOLT-4 cells, a cell line derived from T-cell tumors that does not express CCR4, were used as a negative control instead of MT-2 cells to measure the cytotoxic activity of the bispecific antibodies CCR0001 and CCR0004. MOLT-4 cells were labeled with calcein-AM and suspended in the assay medium using the same method as MT-2 cells described above.
[0378] Figure 14C The table below shows the results of adding T-LAK to the negative control cells MOLT-4 and measuring the cytotoxic activities of CCR0001 and CCR0004.
[0379] The EC50 and Emax values (N=3) are shown in the table below.
[0380] [Table 9] *One of the three tests could not be calculated, so the average of the two tests is recorded. SD was not calculated. NC: Not calculated.
[0381] For MOLT-4 cells, a T-cell tumor line that does not express CCR4, both EC50 and Emax values showed significantly lower cytotoxic activity compared to CCR4-expressing cells. These results demonstrate that the bispecific antibodies CCR0001 and CCR0004 are antibodies that specifically target cells expressing CCR4.
[0382] <Example 4> Cytotoxic activity of anti-CCR4 / anti-TRBC1 bispecific antibody In this embodiment, in order to evaluate the in vitro efficacy of the anti-CD1a / anti-TRBC1 bispecific antibody prepared in Example 1, target cells CCRF-CEM9 were cultured with T-LAK (effective cells) sensitized with anti-TRBC1 antibody in the presence of specific antibody. The cell viability of the target cells was measured using fluorescent pigment (calcein activity) as an indicator, and the effector cell-dependent cytotoxic activity was evaluated.
[0383] The target cells CCRF-CEM9 expressed CD1a and TRBC2, which, as described in Example 2, were obtained by monocloning the CCRF-CEM cell line from TALL.
[0384] The determination of cytotoxic activity was performed using the same method as described in Example 3.
[0385] result Figure 15 The table below shows the results of adding T-LAK to CCRF-CEM9 cells from TALL expressing CD1a and measuring the cytotoxic activity of the bispecific antibodies CD1a1001 and CD1a1004.
[0386] The EC50 and Emax values (N=3) are shown in the table below.
[0387] [Table 10]
[0388] T-LAK was added to CCRF-CEM9 cells, and the cytotoxic activities of CD1a1001 and CD1a1004 were measured. The results showed that the EC50 values for both were 2.9 pM, and the Emax values were 94.2% and 77.0%, respectively. Based on these results, it is concluded that the anti-CD1a antibody and the bispecific antibody against TRBC1 exhibit very strong cytotoxic activity against CD1a and TRBC2-expressing cells.
[0389] <Example 5> Cytotoxic activity of anti-CCR4 / anti-TRBC2 bispecific antibody In this embodiment, in order to evaluate the in vitro efficacy of the anti-CCR4 / anti-TRBC2 bispecific antibody prepared in Example 1, target cells MT-2 were cultured with T-LAK cells (effective cells) sensitized with anti-TRBC2 antibody in the presence of the bispecific antibody. The cell viability of the target cells was measured using fluorescent pigment (calcein activity) as an indicator to evaluate the effector cell-dependent cytotoxic activity.
[0390] result Figure 16 The results are obtained by adding anti-TRBC2 antibody to MT-2 cells, an ATL-derived cell line expressing CCR4, to sensitize T-LAK cells, and measuring the cytotoxic activity of CCR0010. EC50 and Emax values (N=3) are shown in the table below.
[0391] [Table 11]
[0392] T-LAK cells were sensitized with anti-TRBC2 antibody in MT-2 cells, and the cytotoxic activity of CCR0010 was measured. The results showed that the bispecific antibody CCR0010, recognizing both CCR4 and TRBC2, exhibited EC50 of 1677.0 pM and Emax of 81.4% activity against CCR4-expressing cells. Therefore, it is considered that the bispecific antibody recognizing both CCR4 and TRBC2 exhibits similar cytotoxic activity against ATL cell lines expressing CCR4, as the bispecific antibody recognizing both CCR4 and TRBC1.
[0393] <Example 6> Cytotoxic activity of anti-CD1a / anti-TRBC2 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CD1a / anti-TRBC2 bispecific antibody prepared in Example 1, target cells JM were cultured with anti-TRBC2 antibody-sensitized T-LAK cells (effective cells, prepared according to the method described in Example 2) in the presence of the bispecific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The cytotoxic activity was determined using the same method described in Example 3. Target cells JM were a cell line from TALL expressing CD1a and TRBC1. JM cells were purchased from the RIKEN Bio Research Center (RCB0537). They were cultured in RPMI medium containing 10% FBS in a 5% CO2, 37°C incubator, and passaged 2–3 times per week.
[0394] result Figure 17 The results were obtained by sensitizing T-LAK cells from the TALL cell line JM cells expressing CD1a with anti-TRBC2 antibody and measuring the cytotoxic activity of the bispecific antibodies CD1a1003 and CD1a1006.
[0395] The EC50 and Emax values (N=3) are shown in the table below.
[0396] [Table 12]
[0397] T-LAK was added to JM cells, and the cytotoxic activities of CD1a1003 and CD1a1006 were measured. The results showed EC50 values of 22.5 pM and 12.9 pM, respectively, and Emax values of 90.1% and 70.1%, respectively. Based on these results, it is concluded that the anti-CD1a antibody and the anti-TRBC2 bispecific antibody exhibit very strong cytotoxic activity against CD1a and TRBC1-expressing cells.
[0398] <Example 7> Cytotoxic activity of anti-CCR9 / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CCR9 / anti-TRBC1 bispecific antibody prepared in Example 1, target cells CCRF-CEM9 were cultured with T-LAK (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cells CCRF-CEM9 express CCR9 and TRBC2, and as described in Example 2, they are obtained by monocloning the CCRF-CEM cell line from TALL. Cytotoxic activity was determined using the same method as described in Example 3.
[0399] result Figure 18 The results were obtained by adding T-LAK to the CCR9-expressing TALL-derived cell line CCRF-CEM9 and measuring the cytotoxic activity of the bispecific antibodies CCR9-1002 and CCR9-1004.
[0400] The EC50 and Emax values (N=3) are shown in the table below.
[0401] [Table 13]
[0402] T-LAK was added to CCRF-CEM9 cells, and the cytotoxic activities of CCR9-1002 and CCR9-1004 cells were measured. The results showed EC50 values of 29.1 pM and 6.6 pM, respectively, and Emax values of 85.9% and 94.5%, respectively. Based on these results, it is concluded that the bispecific antibodies against CCR9 and TRBC1 exhibit very strong cytotoxic activity against CCR9 and TRBC2-expressing cells.
[0403] <Example 8> Cytotoxic activity of anti-CXCR4 / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CXCR4 / anti-TRBC1 bispecific antibody prepared in Example 1, target cells CCRF-CEM9 were cultured with T-LAK (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cells CCRF-CEM9 express CXCR4 and TRBC2 and, as described in Example 2, are obtained by monocloning the CCRF-CEM cell line from TALL. Cytotoxic activity was determined using the same method as described in Example 3.
[0404] result Figure 19 The results were obtained by adding T-LAK to CCRF-CEM9 cells, a TALL-derived cell line expressing CXCR4, and measuring the cytotoxic activity of the bispecific antibodies CXCR4-1002 and CXCR4-1004.
[0405] The EC50 and Emax values (N=3) are shown in the table below.
[0406] [Table 14]
[0407] T-LAK was added to CCRF-CEM9 cells, and the cytotoxic activities of CD1a1001 and CD1a1004 were measured. The results showed EC50 values of 0.31 pM and 0.73 pM, respectively, and Emax values of 88.3% and 95.6%, respectively. Based on these results, the anti-CXCR4 / anti-TRBC1 bispecific antibody is considered to exhibit very potent cytotoxic activity against CXCR4 and TRBC2-expressing cells.
[0408] <Example 9> Cytotoxic activity of anti-CCR8 / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CCR8 / anti-TRBC1 bispecific antibody prepared in Example 1, target cells were cultured with T-LAK cells (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cell line MT-1 is a CCR8-expressing cell line derived from ATL. Cytotoxic activity was determined using the same method described in Example 3. MT-1 cells were purchased from the JCRB cell bank (National Research and Development Corporation Pharmaceutical Foundation, Health and Nutrition Institute) (JCRB1209). Cells were cultured in RPMI medium containing 10% FBS in a 5% CO2, 37°C incubator, passaged 2-3 times per week.
[0409] result Figure 20 The results were obtained by adding T-LAK to MT-1 cells, an ATL-derived cell line expressing CCR8, and measuring the cytotoxic activities of CCR81001 and CCR81002. EC50 and Emax values (N=3) are shown in the table below.
[0410] [Table 15]
[0411] T-LAK was added to MT-1 cells, and the cytotoxic activities of CCR81001 and CCR81002 were measured. The results showed EC50 values of 23.5 pM and 31.4 pM, and Emax values of 89.9% and 97.1%, respectively. Based on these results, the bispecific antibodies CCR81001 and CCR81002, which recognize CCR8 and TRBC1, are considered to exhibit very potent cytotoxic activity against CCR8-expressing cells.
[0412] <Example 10> Cytotoxic activity of anti-TIGIT / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-TIGIT / anti-TRBC1 bispecific antibody prepared in Example 1, target cells were cultured with T-LAK cells (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cell line, ILT-Mat, is an ATL-derived cell line expressing TIGIT. Cytotoxic activity was determined using the same method described in Example 3. ILT-Mat cells were purchased from the RIKEN Bio Research Center (RCB0475). Cells were cultured in RPMI medium containing 320 IU / mL IL-2 and 10% FBS in a 5% CO2, 37°C incubator, and passaged 2–3 times per week.
[0413] result Figure 21 The results were obtained by adding T-LAK to ILT-Mat cells, an ATL-derived cell line expressing TIGIT, and measuring the cytotoxic activities of TIGIT2001 and TIGIT2002. EC50 and Emax values (N=3) are shown in the table below.
[0414] [Table 16]
[0415] T-LAK was added to ILT-Mat cells, and the cytotoxic activities of TIGIT2001 and TIGIT2002 were measured. The results showed EC50 values of 3.4 pM and 5.6 pM, and Emax values of 105.1% and 91.9%, respectively. Based on these results, the bispecific antibodies TIGIT2001 and TIGIT2002, which recognize TIGIT and TRBC1, are considered to exhibit very potent cytotoxic activity against TIGIT-expressing cells.
[0416] <Example 11> Cytotoxic activity of anti-CD30 / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CD30 / anti-TRBC1 bispecific antibody prepared in Example 1, target cells were cultured with T-LAK cells (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cell line DL40 is a PTCL-derived cell line expressing CD30. Cytotoxic activity was determined using the same method described in Example 3. DL40 cells were purchased from the JCRB Cell Bank (National Research and Development Corporation Pharmaceutical Foundation, Health and Nutrition Institute) (JCRB1337). Cells were cultured in RPMI medium containing 10% FBS in a 5% CO2, 37°C incubator, passaged 2-3 times per week.
[0417] result Figure 22 The results are obtained by adding T-LAK to DL40 cells, a PTCL-derived cell line expressing CD30, and measuring the cytotoxic activities of CD301001 and CD301003. EC50 and Emax values (N=3) are shown in the table below.
[0418] [Table 17]
[0419] T-LAK was added to DL40 cells, and the cytotoxic activities of CD301001 and CD301003 were measured. The results showed EC50 values of 151.1 pM and 14.5 pM, respectively, and Emax values of 89.1% and 95.7%, respectively. Based on these results, it is concluded that the anti-CD30 antibody and the bispecific antibodies against TRBC1, CD301001 and CD301003, exhibit very potent cytotoxic activity against CD30-expressing cells.
[0420] <Example 12> Cytotoxic activity of anti-CD40L / anti-TRBC1 bispecific antibody In this embodiment, to evaluate the in vitro efficacy of the anti-CD40L / anti-TRBC1 bispecific antibody prepared in Example 1, target cells were cultured with T-LAK cells (effective cells) in the presence of the specific antibody. Cell viability was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. The target cells, MOLT3, are TALL-derived cell lines expressing CD40L (CD154). Cytotoxic activity was determined using the same method described in Example 3. MOLT3 cells were purchased from the RIKEN Bio Research Center (RCB9048). They were cultured in RPMI medium containing 10% FBS at 37°C with 5% CO2, and passaged 2–3 times per week.
[0421] result Figure 23 The results are obtained by adding T-LAK to MOLT3 cells, a TALL-derived cell line expressing CD40L (CD154), and measuring the cytotoxic activities of CD40L1007 and CD40L1008. EC50 and Emax values (N=3) are shown in the table below.
[0422] [Table 18]
[0423] T-LAK was added to MOLT3 cells, and the cytotoxic activities of CD40L1007 and CD40L1008 were measured. The results showed EC50 values of 125.0 pM and 49.1 pM, and Emax values of 67.7% and 72.7%, respectively. Based on these results, it is concluded that the anti-CD40L antibody and the bispecific antibodies CD40L1007 and CD40L1008 against CD40L (CD154) expressing cells exhibit very potent cytotoxic activity.
[0424] <Example 13> Evaluation of the cytotoxic activity of a bispecific antibody using anti-CD3 antibodies in T-cell tumors CD3 is expressed identically in both normal T cells and tumor T cells. Bispecific antibodies targeting CD3 and tumor antigens simultaneously bind to both the CD3 antigen expressed in malignant T cells and the target antigen expressed in malignant T cells, thereby linking malignant tumor cells together. Figure 1A Therefore, it is very likely that the therapeutic effect of bispecific antibodies will not be fully achieved.
[0425] In this embodiment, the cytotoxic activity of a bispecific antibody using an anti-CD3 antibody against CD3-expressing tumor cell lines and CD3-knockout tumor cell lines was evaluated. Furthermore, the same experiment was performed using a bispecific antibody using an anti-TRBC1 antibody.
[0426] Anti-CD1a / anti-CD3 bispecific antibody CD1a1016 and anti-CD1a / anti-TRBC1 bispecific antibody CD1a1005 were prepared using the method described in Example 1. The CD1a binding moieties of CD1a1016 and CD1a1005 contain the same amino acid sequence. The CD3 binding moieties of CD1a1016 were designed based on the anti-CD3 antibody described in U.S. Patent No. 5,821,337.
[0427] [Table 19]
[0428] HPB-ALL and HPB-ALL CD3 KO cells were cultured with T-LAK (effective cells) in the presence of various bispecific antibodies. Cell viability of the target cells was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxicity. HPB-ALL target cells expressed CD1a, CD3, and TRBC2. HPB-ALL CD3 KO cells were obtained by knocking out the CD3 gene from the HPB-ALL cell line derived from TALL using the CRSPR-Cas9 method. Cytotoxicity was determined using the same method described in Example 3. HPB-ALL target cells were purchased from the RIKEN Bio Research Center (RCB1935). They were cultured in RPMI 1640 medium containing 10% FBS in a 5% CO2 incubator at 37°C, passaged 2–3 times per week.
[0429] result Figure 24 The results showed that T-LAK was added to HPB-ALL cells, a TALL cell line expressing CD3, and HPB-ALL CD3 KO cells with CD3 knockout, and the cytotoxic activities of the anti-CD1a / anti-CD3 bispecific antibody CD1a1016 and the anti-CD1a / anti-TRBC1 bispecific antibody CD1a1005 were measured.
[0430] The EC50 and Emax values (N=3) are shown in the table below.
[0431] [Table 20]
[0432] Compared to when CD3 is not expressed, the EC50 of the anti-CD1a / anti-CD3 bispecific antibody CD1a1016 was approximately 10-fold higher and the Emax was lower in target cells expressing CD3. Based on these results, it is believed that the cytotoxic activity of bispecific antibodies against CD3 is weakened when CD3 is expressed on the target cell side and applied to effector cells.
[0433] The EC50 and Emax of the anti-CD1a / anti-TRBC1 bispecific antibody CD1a1005 did not vary significantly depending on the target cell.
[0434] <Example 14> Cytotoxic activity of a bispecific antibody against TRBC2 against TRBC1-expressing and TRBC2-expressing tumor cells. In this embodiment, the cytotoxic activity of the anti-CD1a / anti-TRBC2 bispecific antibody CD1a1006 prepared in Example 1 against TRBC1-positive and TRBC2-positive tumor cell lines was compared.
[0435] Target cells CCRF-CEM9 and JM cells were sensitized with anti-TRBC2 antibody and cultured as T-LAK (effective cells). Cell viability of the target cells was measured using fluorophore (calcein activity) as an indicator to evaluate effector cell-dependent cytotoxic activity. CCRF-CEM9 cells are a TALL-derived cell line expressing CD1a and TRBC2. JM cells are a TALL-derived cell line expressing CD1a and TRBC1. Cytotoxic activity was determined using the same method described in Example 3.
[0436] The cytotoxic activity of the anti-CD1a / anti-TRBC1 bispecific antibody against the TRBC2-positive tumor cell line CCRF-CEM9 was evaluated in Example 4. Furthermore, the cytotoxic activity of the anti-CD1a / anti-TRBC2 bispecific antibody CD1a1006 against the TRBC1-positive tumor cell line JM was also demonstrated in Example 6.
[0437] result Figure 25 The results show that T-LAK cells were sensitized with anti-TRBC2 antibody after adding anti-TRBC2 antibody to CCRF-CEM9 cells from TALL expressing TRBC2 and JM cells from TALL expressing TRBC1, and the cytotoxic activity of the anti-CD1a / anti-TRBC2 bispecific antibody CD1a1006 was measured. EC50 and Emax values (N=3) are shown in the table below.
[0438] [Table 21]
[0439] For the target cells CCRF-CEM9 and JM, the EC50 values were 28.4 pM and 18.0 pM, respectively, and the Emax values were 33.0% and 72.8%, respectively. These results indicate that the anti-CD1a / anti-TRBC2 bispecific antibody exhibits high cytotoxic activity against cells expressing CD1a and TRBC1, and low cytotoxic activity against cells expressing CD1a and TRBC2. Furthermore, as shown in Example 4, when the effector antibody was TRBC1, it exhibited very potent cytotoxic activity against the target cell CCRF-CEM9. These results suggest that the effector antibody is important for recognizing subtypes not expressed in tumor cells.
[0440] <Example 15> Evaluation of in vivo antitumor effect In this embodiment, the in vivo antitumor effect of the anti-CD1a / anti-TRBC2 bispecific antibody CD1a1006 was studied.
[0441] Cell preparation JM cells are a cell line derived from TALL and express CD1a and TRBC1. They were purchased from the Cell Materials Development Laboratory of RIKEN (cell number RCB1164, product number: RCB0537). JM-Luc cells, which stably express the luciferase gene in JM cells, were used. JM-Luc cells were cultured in RPMI 1640 medium containing 10% FBS in a 5% CO2 incubator at 37°C. The cultured cells were used for in vivo antitumor efficacy assays.
[0442] experimental animals Animal species: Mouse System: NOD / Shi-scid, IL-2RγKO JiC (NOG) Supplier: CLEA Co., Ltd., Japan Age: 6 weeks (when accepted).
[0443] Preparation of PBMC PBMCs were purchased from Hemacare (product number: PB009C-3, Lot No.: 22074722). Frozen PBMCs (1×10⁸ cells / vial) were thawed in a thermostat at approximately 37°C. Cell suspension was collected using a pipette and slowly added dropwise to 50 mL centrifuge tubes. Empty vials were rinsed with thawing media (Hanks' balanced salt solution (-) containing 10% FBS) and slowly added dropwise to the centrifuge tubes for mixing. Centrifugation was performed (room temperature, 400×g, 5 min). After removing the supernatant, the cells were resuspended in washing buffer (25 mL D-PBS containing 0.005% FBS + 100 μL 0.5 M EDTA). The cells were then diluted 2-fold using trypan blue, and the viable cell count was determined. Centrifuge again (room temperature, 400×g, 5 minutes), remove the supernatant by aspiration, and prepare a cell suspension of 1×10⁸ cells / mL using RPMI 1640 medium.
[0444] Porting of PBMC The prepared PBMC suspension was placed on ice and placed in the feeding room. Within 2 hours after preparation, NOG mice were disinfected with alcohol swabs and intravenous transplantation was performed using a 1 mL disposable syringe and a 27G syringe (Terumo Co., Ltd.) at a dose of 0.1 mL (1×10⁷ cells / mouse) per mouse. This was designated as "Day 10".
[0445] Preparation of JM-Luc cells JM-Luc cells were recovered from culture on Day 0. Centrifugation was performed (room temperature, 400×g, 5 min). After removing the supernatant, the cells were washed with PBS and centrifuged again (room temperature, 400×g, 5 min). The supernatant was removed, diluted appropriately with PBS, stained with trypan blue, and the cells were counted to a concentration of 1×10⁷ cells / mL. The prepared cells were stored on ice from resuscitation until transplantation.
[0446] JM-Luc cell transplantation The prepared JM-Luc cell suspension was placed on ice and placed in the feeding room. Within 2 hours after preparation, NOG mice were disinfected with alcohol swabs and intravenous transplantation was performed in the tail vein using a 1 mL disposable syringe and a 27G syringe (Terumo Co., Ltd.). This was designated as "Day 0".
[0447] Antibody preparation CD1a1006 was prepared using PBS with antibody dosages of 0.05 mg / kg (0.01 mg / mL), 0.15 mg / kg (0.03 mg / mL), 0.5 mg / kg (0.1 mg / mL), 1.5 mg / kg (0.3 mg / mL), and 5 mg / kg (1.0 mg / mL).
[0448] Antibody administration On Days 1, 7, 10, 14, 17, 21, and 25, the tail was disinfected with alcohol swabs, and the prepared antibody solution was transplanted into the tail vein at a dose of 0.1 mL per animal using a 1 mL disposable syringe and a 27G syringe (Terumo Co., Ltd.).
[0449] Methods for analyzing anti-tumor effects On Days 14 and 28, for all surviving individuals, the luminescence of JM-Luc cells was measured using an IVIS imaging system (Revvity). On each IVIS measurement day, fluorescein was administered intraperitoneally at 150 mg / kg (10 mL / kg). Under isoflurane inhalation anesthesia, the individuals were positioned supine in the IVIS room. Approximately 5 to 20 minutes after fluorescein administration, with the whole body as the region of interest (ROI), the total flux was measured approximately every minute. For any measurement day and any individual, the maximum value of the total flux approximately every minute was set as the measured value for that individual.
[0450] result The IVIS measurements for each group on Day 14 and 28 are visualized and shown below. Figure 26 The tumor distribution image is shown in Figure 27 On Day 14, the IVIS value of Group 1 was 56.34±68.05×10⁵ p / s. In contrast, the IVIS values of Groups 2 to 6, which received CD1a1006, were 11.74±2.59×10⁵ p / s, 7.17±0.14×10⁵ p / s, 7.10±2.01×10⁵ p / s, 8.54±0.32×10⁵ p / s, and 8.64±1.05×10⁵ p / s, respectively.
[0451] Furthermore, the IVIS value of Group 1 on Day 28 was 3951.23±5229.34×10⁵ p / s, while the IVIS values of Groups 2 to 6, which received CD1a1006, were 7.43±0.99×10⁵ p / s, 7.81±0.66×10⁵ p / s, 6.43±0.29×10⁵ p / s, 7.66±0.59×10⁵ p / s, and 9.40±0.20×10⁵ p / s, respectively.
[0452] These results indicate that CD1a1006 has the efficacy to inhibit the implantation and subsequent proliferation of JM-Luc cells.
[0453] <Example 16> Identification of ATL patients with T-cell dysfunction Use reagents Buffer solution: Prepared by mixing 500 mL of PBS (Nacalai Tesque, 14249-94) and 10 mL of HI-FBS (SIGMA). Clear Back (MBL, MT-001) The active dye eFluor780 (invitrogen, 65-0865-14) can be fixed. Transcription factor buffer kit (BD, 562574) TF Fix / Perm Buffer (4×) (51-9008100): Use after a 4-fold dilution with TF dilution buffer. TF dilution buffer (51-9008101) TF Perm / Wash Buffer (5×) (51-9008102): Use after a 5-fold dilution with distilled water.
[0454] [Table 22]
[0455] The staining antibodies are shown in the table below.
[0456] [Table 23] ※BV421, BV711: Abbreviations for Brilliant Violet421 (registered trademark) and Brilliant Violet711 (registered trademark).
[0457] Methods of staining cell surface and intracellular cells After centrifuging healthy human PBMCs or PBMCs from ATL patients (500g x 2 min), the supernatant was removed, and ClearBack was added. After incubating at room temperature for 5 min, various cell surface antibodies were added to the buffer, and the reaction was carried out at 4°C for 30 min. After the reaction, the cells were centrifuged again (500g x 2 min) and the supernatant was discarded, thus performing two cell washes. TF Fix / Perm buffer from the transcription factor buffer kit was added, and the cells were incubated on ice for 45 min for fixation and permeation. After centrifugation (700g x 2 min), TF Perm / Wash buffer was added, and the cells were centrifuged again (700g x 2 min), and the supernatant was discarded, thus performing three cell washes. Anti-CTLA-4 antibody or allotype control antibody was added to the TF Perm / Wash buffer, and the reaction was carried out at room temperature for 45 min. After the reaction, TF Perm / Wash buffer was added and the cells were centrifuged (700g × 2 min). The supernatant was discarded, and the cells were washed twice. The signal was quantified by flow cytometry analysis using BD FACSymphony A1 (BD Biosciences). The analysis software used was FlowJo_v10.8.1.
[0458] result [Table 24]
[0459] Figure 28 The figures above show the PD-1 and CTLA-4 positive cell rates in CD3-positive, CD4-positive, CADM1-negative normal T cells. The PD-1 positive cell rate in normal T cells derived from PBMCs in healthy individuals is 1.5–6.0%, while in ATL patient 1, the PD-1 positive cell rate is 16.0%, indicating a significantly higher rate. Furthermore, for CTLA-4, virtually no difference in the positive cell rate was observed between healthy individuals and ATL patients. Therefore, it is believed that a subset of ATL patients exhibit T cell dysfunction through hyperexpression of PD-1.
[0460] <Example 17> Analysis of bispecific antibody-dependent cytotoxic activity in ATL patients Use the following reagents. FBS (NICHIREI, 175012, Lot. 19J00C) Steady-Glo (Promega, E2520) RPMI1640 (Nacalai Tesque, 30264-85) 1M Hepes (Nacalai, 17557-94) 100x Sodium Pyruvate (gibco, 11360-070) 100x 2-ME (Wako, 198-15781).
[0461] In this embodiment, the anti-CD1a / anti-TRBC1 bispecific antibody prepared in Example 1 was used to verify the cytotoxic activity of effector cells derived from ATL patients (ATL patient 1, ATL patient 2) and healthy individuals (healthy individual 1) on target cells used in Example 16.
[0462] MOLT-4-Luc target cells were cultured with PBMCs (effector cells) from healthy individuals or ATL patients in the presence of bispecific antibodies. Cell viability of the target cells was measured using luminescent enzyme activity (luciferase activity) as an indicator to evaluate effector cell-dependent cytotoxic activity.
[0463] The target cell line MOLT-4-Luc cells were obtained by introducing the luciferase gene into the TALL-derived cell line MOLT-4 cells using a plasmid vector.
[0464] method Bispecific antibodies were prepared to a final concentration of 1 nM to 10 fM using RPMI 1640 medium (TDCC medium) containing 10% FBS, 10 mM HEPES, 1 mM sodium pyruvate and 0.1 mM 2-ME, and added to 384-well flat-bottomed culture plates.
[0465] To assess cytotoxic activity using bispecific antibodies targeting the antigen-binding sites of CD1a and TRBC1, the required amount of MOLT-4-Luc cells (target cells) were recovered from the culture medium, suspended in TDCC medium, and the cell count was performed. These cells were then added to 384-well flat-bottomed culture plates prepared with bispecific antibodies. The required amount of effector cells were recovered, suspended in TDCC medium, and the cell count was performed. These cells were then added to 384-well flat-bottomed culture plates prepared with bispecific antibodies. The ratio of effector cells to labeled target cells was 10:1. The plates containing bispecific antibodies, labeled target cells, and effector cells were incubated at 37°C with 5% CO2. After 72 hours, 25 μL of Steady-Glo was added to each well, and after 5 minutes, the luminescence of luciferase in surviving target cells was measured using a microplate reader (Bio Tek, Cytation 5). The percentage of cytotoxicity of target cells was calculated based on the luciferase luminescence value to evaluate the bispecific antibody-dependent cytotoxic activity.
[0466] The percentage of cytotoxicity is calculated as follows.
[0467] The maximum luminescence value of the labeled target cells (toxicity percentage = 0%) was obtained from wells incubated with labeled target cells and effector cells in the absence of any bispecific antibodies.
[0468] Calculate the percentage of cytotoxicity using the following formula: Cytotoxicity percentage = 100 - [100 × (luminescence value of target cells in the presence of bispecific antibody) / (maximum luminescence value)] .
[0469] The S-shaped dose-response curve was calculated using Prism software (GraphPad Software Inc.), which yielded the EC50 value (50% effective concentration) and the Emax value (maximum activity value).
[0470] result Figure 29 The results were obtained by measuring the cytotoxic activity of PBMCs derived from healthy individuals (healthy individual 1) and PBMCs derived from ATL patients (ATL patient 1 and ATL patient 2) against luciferase-positive MOLT-4-Luc cells under the condition of adding anti-CD1a / anti-TRBC1 bispecific antibody (CD1a1005).
[0471] The EC50 and Emax values are shown in the table below.
[0472] [Table 25]
[0473] The Emax of healthy person 1 was 79.3%, while that of ATL patient 1 was 83.7%, showing activity comparable to that of healthy individuals. Furthermore, the Emax of ATL patient 2 was 45.3%, demonstrating toxic activity against target cells.
[0474] The results of Example 16 showed that ATL patient 1 had higher PD-1 expression compared to healthy individuals, suggesting possible T cell dysfunction. Furthermore, the results of Example 17 showed that ATL patient 1 exhibited bispecific antibody-dependent cytotoxic activity against target cells similar to or higher than that in healthy individuals. Therefore, it can be concluded that a subset of ATL patients are in a state of T cell dysfunction, and bispecific antibodies recognizing TRBCs are considered capable of inducing cytotoxic activity even in patients with T cell dysfunction.
[0475] <Example 18> Single-cell analysis of T cells in ATL patients Peripheral blood mononuclear cells (PBMCs) were obtained from healthy individuals or ATL patients using standard procedures. Dead cells were removed using the Miltenyi Biotec DeadCell Removal Kit. T cells were then isolated and collected using the Miltenyi Biotec Pan T Cell Isolation Kit. Single-cell droplets were prepared using the Chromium Next GEM Single Cell 5'Reagent Kits v2 to generate cDNA. The resulting cDNA was sequenced and analyzed using a next-generation sequencer, the HiSeq® system (Illumina).
[0476] Preprocessing and analysis of the obtained sequencing data were performed using R software (version 4.1.3). After Cell Ranger analysis, secondary analysis was performed using Seurat (version 4.3.0.1). Cell quality management was implemented using SoupX for extracellular mRNA contamination removal and DoubletFinder for double-cell prediction and removal. Data were filtered based on RNA count and mitochondrial gene proportions. GEX data were normalized using SCTransform, and principal component analysis (PCA) and UMAP (uniform manifold approximation and projection) were performed for dimensionality reduction. Harmony was applied for data integration and batch effect correction. Subsequently, for CD8-positive T cell data, the expression levels of the following genes were analyzed, and the biological function of the CD8-positive T cells was scored using Seurat's AddModuleScore.
[0477] [Table 26]
[0478] The results are shown in Figure 30 See Table 27. In PBMCs derived from ATL patients 3 and 4, the levels of activation, pro-survival, and cytotoxicity were significantly lower compared to healthy individuals. Therefore, this indicates that CD8-positive T cells in ATL patients 3 and 4 were in a state of dysfunction.
[0479] [Table 27]
[0480] <Example 19> Analysis of bispecific antibody-dependent cytotoxic activity in ATL patients Instead of the anti-CD1a / anti-TRBC1 bispecific antibody, an anti-CD1a / anti-TRBC2 bispecific antibody (CD1a1003) was used, and PBMCs obtained in Example 18 were used as effector cells. Otherwise, the cytotoxic activity of PBMCs against target cells was measured in the same manner as in Example 17.
[0481] The results are shown in Figure 31 Although CD8-positive T cells in PBMCs derived from ATL patients 3 and 4 were in a state of dysfunction, concentration-dependent cytotoxic activity was induced by anti-CD1a / anti-TRBC2 bispecific antibodies, similar to that induced by PBMCs derived from healthy individuals. Therefore, it is confirmed that bispecific antibodies recognizing TRBCs can induce cytotoxic activity even in patients with T cell dysfunction.
Claims
1. A therapeutic agent, which is a therapeutic agent for T-cell tumors in subjects with T-cell dysfunction containing bispecific antigen-binding molecules, wherein, Bispecific antigen-binding molecules include: (1) at least one portion of the target tumor antigen specifically bound to T-cell tumor cells, and (2) At least one part of an antigen that specifically binds to a subtype of a normal T cell target antigen; Specifically, the target tumor antigen expressed in T-cell tumor cells is absent in normal T cells, or even if it is present, the normal T cells are not actually activated when a bispecific antigen-binding molecule binds to an antigen present in normal T cells that is identical to the target tumor antigen. Normal T cells are activated by the binding of bispecific antigen-binding molecules to target antigens on the side of normal T cells, and There is a sufficient proportion of normal T cell side target antigen subtypes to provide a sufficient number of activated T cells for the treatment of T cell tumors.
2. The therapeutic agent according to claim 1, wherein, The subtypes of target antigens on normal T cells are not any of the subtypes of antigens expressed in T cell tumor cells.
3. The therapeutic agent according to claim 1 or 2, wherein, The subtype of the antigen that serves as a target antigen for normal T cells is the TRBC (T cell receptor β homeostasis region). The subtype expressed in T-cell tumor cells is TRBC1. The subtype of target antigen on the side of normal T cells is TRBC2.
4. The therapeutic agent according to claim 1 or 2, wherein, TRBC is a subtype of antigen that serves as a lateral target antigen for normal T cells. The subtype expressed in T-cell tumor cells is TRBC2. The subtype of target antigen on the side of normal T cells is TRBC1.
5. The therapeutic agent according to claim 1 or 2, wherein, TRBC is a subtype of antigen that serves as a lateral target antigen for normal T cells. T-cell tumor cells are TRBC1-negative and TRBC2-negative. The subtypes of target antigens on normal T cells are TRBC1 or TRBC2.
6. The therapeutic agent according to claim 1 or 2, wherein, The subtype of target antigen on the side of normal T cells is TRBC1. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC1 on normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:10 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:11, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:12 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:13 The light chain CDR2, and containing the amino acid sequence described in SEQ ID NO:14 The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:
15.
7. The therapeutic agent according to claim 6, wherein, At least one portion of the TRBC1-specific binding region to normal T cells comprises a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:4 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:5, or It contains a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:148 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:
149.
8. The therapeutic agent according to claim 1 or 2, wherein, The subtype of target antigen on the side of normal T cells is TRBC2. The bispecific antigen-binding molecule comprises at least one portion that specifically binds to TRBC2 on normal T cells, wherein the at least one portion comprises a VH domain and a VL domain. The VH domain includes: Heavy chain CDR1 containing the amino acid sequence described in SEQ ID NO:16 Heavy chain CDR2 containing the amino acid sequence described in SEQ ID NO:17, and Heavy chain CDR3 containing the amino acid sequence described in SEQ ID NO:18 The VL structure domain includes: The light chain CDR1 containing the amino acid sequence described in SEQ ID NO:19 The light chain CDR2, containing the amino acid sequence described in SEQ ID NO:20, and The light chain CDR3 contains the amino acid sequence described in SEQ ID NO:
21.
9. The therapeutic agent according to claim 8, wherein, At least one portion that specifically binds to TRBC2 in normal T cells includes a heavy chain variable region VH that is at least 90% identical to the amino acid sequence described in SEQ ID NO:6 and a light chain variable region VL that is at least 90% identical to the amino acid sequence described in SEQ ID NO:
7.
10. The therapeutic agent according to claim 1 or 2, wherein, T-cell tumors are T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma or mature T-cell tumors.
11. A therapeutic agent, as described in claim 1 or 2, for a method of treating a T-cell tumor in a subject with T-cell dysfunction, wherein... The aforementioned treatment method includes: identifying a subtype expressed in the subject's T-cell tumor cells, and administering a therapeutic agent to the subject; the therapeutic agent comprises a bispecific antigen-binding molecule, the bispecific antigen-binding molecule comprising at least one portion that specifically binds to a normal T-cell side-target antigen, the subtype of which is different from the subtype identified as being expressed in the subject's T-cell tumor cells.
Citation Information
Patent Citations
Antibodies against human CD154
JP2003526371A
Method for producing trialkoxysilane
JP2024066502A
Protein-based T-cell receptor knockdown
US10730942B2
Immunoglobulin variants
US5821337A
Antibodies to human CD154
WO2001068860A1
